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ABSTRACT
Background:
Echocardiography is widely established for prenatal diagnosis of congenital heart disease,
arrhythmias, and other hemodynamic alterations in the fetal and neonatal circulation. 
Objectives:
The objective of the present series of studies was to evaluate by means of
echocardiography the etiology and outcome of fetuses and neonates with alterations in
cardiac hemodynamics.
Subjects:
The fetal study population comprised altogether 442 fetal cases with prenatal diagnosis of
intrauterine structural or functional cardiovascular disease. These fetuses had been
referred to a pediatric cardiologist at the Hospital for Children and Adolescents for
detailed echocardiography between January 1983 and December 2001. Inclusion criteria
for fetal studies were an intrauterine structural or functional cardiovascular disease
confirmed postnatally or at post-mortem examination (Studies I-II) or documented
intrauterine arrhythmia and complete follow-up in utero and after birth (III).
The neonatal study population consists of 63 newborn infants born in the maternal unit of
the Helsinki University Hospital and treated in the neonatal intensive care unit of the
same hospital. Infants with a birth weight less than 1500 g and indwelling arterial lines
were enrolled if birth weight was less than 2SD (SGA) or within ± 1SD range (AGA)
(study IV). 
Main results:
In the whole fetal study population, the prognosis was poor if the fetus was hydropic.
After the newborn period, the prognosis was good; there was however, some neurological
morbidity in all study groups. 
Study I: The prognosis for fetuses with in-uterodiagnosed structural heart defect was
poor. The outcome was largely attributable to associated extracardiac malformations and
chromosomal abnormalities. 
Study II: Independent of the etiology of the functional heart disease, the mortality of the
fetuses was high.
Study III: All fetal arrhythmias except atrial extrasystoles were associated with a
moderately high risk for fetal distress. In cases of compromise, fetal and neonatal
prognosis was poor and was an indication for perinatal medication. 
Study IV: In the neonatal study population, the cardiac diameters in relation to weight
after growth retardation were increased. Serum BNP correlated significantly with both
IVSD and LVEDD. 
Conclusions:
Echocardiography is a reliable tool in diagnosis and follow-up of fetuses and neonates
with cardiovascular compromise. The outcome of the fetuses with intrauterine
cardiovascular disease is poor regardless of etiology.
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         1. INTRODUCTION
The origins of fetal and neonatal cardiology go back to the 1950s and 1960s. Dawes et
al., Rudolph and Heymann, and Friedman demonstrated the features of the fetal
circulation. These authors were the first to delineate the physiology necessary for the
well-being and growth of the fetus as well as for the changes which occur at the time of
birth (Dawes et al. 1955; Rudolph and Heymann 1967; Friedman et al. 1983).
The early efforts to monitor fetal well-being were based on electrocardiographic heart
rate monitoring. The evolution of ultrasound in the 1960s and 1970s created new
opportunities to diagnose, treat, and follow up fetal distress. The first fetal ultrasound
studies were made with M-mode echocardiography (Wladimiroff and McGhie 1981;
DeVore et al. 1982; Kleinman et al. 1982) and involved mostly detection of arrhythmias
and reports of structural abnormalities. Winsberg and St John Sutton et al. developed
normal data for fetal hearts from M-mode images. (Winsberg 1972; St John Sutton et al.
1984).
The development of two-dimensional (2D) real-time systems with adequate resolution
permitted accurate definition of intracardiac anatomy, cardiac development, and function.
Lindsey Allan published the first study on echo/anatomic correlates in 1980, and Lange et
al. on normal fetal heart dimensions in Circulation the same year. The development of
pulsed and continuous wave Doppler in quantification of blood flow velocity signals has
enabled evaluation of fetal hemodynamics (Sahn and Mack 2000).  
Fetuses with increased nuchal translucency thickness are at much greater risk for cardiac
defects. This constitutes an indication for targeted fetal echocardiography, to reveal
abnormalities in cardiac structure, rhythm, and function. If these are found, the patient is
referred to a pediatric cardiologist (Allan 2003). Measurement of nuchal translucency is
used at approximately 10 to 14 weeks of pregnancy, and a detailed fetal anatomy scan is
performed between 16 and 20 weeks of gestation. 
Postnatally, a two-dimensional echocardiograph with standard projections permits a
comprehensive and precise anatomic study of the heart. The pulsed- and continuous-wave
Doppler ultrasound techniques offer the possibility of quantifying flow changes in the
aorta, pulmonary arteries, and ductus arteriosus. Color Doppler imaging provides insight
into the shape and character of the flow jets. In newborns with respiratory failure,
detection of right-to-left shunting and elevated pulmonary artery pressure is important to
guide medical management. 
The objective of the present series of studies was to evaluate the prognoses and outcome
of fetuses and neonates diagnosed by echocardiography in regards to alterations in
cardiac hemodynamics. 
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2.  REVIEW OF THE LITERATURE
2.1. PHYSIOLOGY OF THE FETAL CIRCULATION
2.1.1. Characteristics of the Circulation
Particular features characterize fetal cardiac development and circulation. Left and right
circulations work in parallel with intercirculatory connections: the foramen ovale and
ductus arteriosus.
The earliest works concerning fetal circulation were animal studies. These demonstrate
that the right ventricle delivers the majority of its output to the placenta for oxygen
uptake, and the left ventricle delivers its output to the heart, ascending aorta, brain, and
the upper part of the body. The poorly oxygenated blood flows from the superior vena
cava and coronary sinus through across the tricuspid valve into the right ventricle. A
minor portion of the right ventricular output enters the pulmonary circulation (8%); most
of the blood flows through the ductus arteriosus and joins the blood that streams from the
aortic arch (Rudolph and Heymann 1967). Umbilical venous blood from the placenta
joins with the portal venous return from the gastrointestinal tract, and flows into the
inferior vena cava directly through the ductus venosus or through the hepatic circulation.
Approximately 50% of this oxygenated blood passes through the foramen ovale into the
left atrium and ventricle (Kiserud et al. 1991). 
 
The human fetus has right ventricular dominance; the right ventricle ejects a stroke
volume approximately 20% greater than that of the left ventricle (Sutton et al. 1991).
Ventricular minute output increases from 20 to 40 weeks of gestation in the human fetus,
and the right ventricle contributes approximately 60% of the total combined ventricular
output at 38 weeks. From 20 to 30 weeks of gestation, the proportion of pulmonary artery
blood flow of the combined cardiac output increases from 13% to 25%, while the
proportion of foramen ovale blood flow decreases (Räsänen et al. 1996). Of the combined
ventricular outputs, 10 to 25% is distributed to the lungs, and 55 to 60% across the ductus
arteriosus to the descending aorta; 33% of the combined output is ejected by the left
ventricle, and this is mainly distributed to the coronary circulation and the upper part of
the body. Of the combined ventricular output, 10% crosses the aortic isthmus and joins
with the blood from the ductus arteriosus. The upper part of the body contributes
approximately 25%, and the lower from 25 to 30% of the venous return, the remaining 40
to 45% coming from the umbilical veins (Rudolph and Heymann 1967; Rudolph and
Heymann 1970). 
2.1.2. Myocardial Function
Animal models have demonstrated differences in diastolic functions between fetal and
fully developed myocardium, indicating that fetal myocardium is less compliant.
Observations on the diastolic function of the human fetal myocardium are made by
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Doppler echocardiographic blood flow velocity profiles. In the human fetus, peak blood
flow velocity is greater during active filling (atrial contraction) than during the rapid
filling phase, because of the atriosystolic function. This finding indicates diminished
ventricular compliance in the fetal heart (Veille et al. 1999).
The fetus has a limited range of heart rates over which cardiac outputs can be maintained.
Prolonged extreme bradycardia (heart rate less than 50 beats/min.) or tachycardia (heart
rate higher than 200) is known to cause congestive heart failure and hydrops. Some
investigators have stated that alterations in heart rate are the major determinants of
cardiac output. One Doppler ultrasound study in human fetuses demonstrated an inverse
proportionality between cardiac cycle length and right ventricular stroke volume
(Anderson et al. 1987; Reed et al. 1987), but no change in ventricular output and little or
no change in systolic contractile function. The relationship between cardiac cycle length
and stroke volume indicates that the major regulator of cardiac output in the human fetus
is the Frank-Starling mechanism.  
2.2. TRANSITION FROM FETAL TO NEONATAL CIRCULATION
Throughout the latter part of the second and third trimesters, the force developed by the
right and by the left ventricle is similar, even though the right ventricle ejects a
significantly greater stroke volume than the left. The myocardial force in both ventricles
escalates more than tenfold in the period from 20 weeks to term. This increase parallels
growth in heart weight and total body weight (St John Sutton et al. 1984).
At birth, the cardiovascular circulation changes dramatically, two separate circulations in
series replacing the parallel pattern of circulation. There occur closure of the fetal
channels, separation of the umbilical circulation, and cessation of flow through the
foramen ovale. The growing pulmonary blood flow causes an increase in venous return to
the left atrium and an elevation of pressure. Pressure in the right atrium decreases, and the
foramen ovale closes functionally as the result of the reversed pressure gradient between
the atria (Dawes et al. 1955). Shunting through the ductus arteriosus changes from right-
to-left to left-to-right as a result of decreasing pulmonary vascular resistance. The
transition from a fetal to a postnatal circulation is completed by closure of the ductus
arteriosus. 
In normal neonates, during the transition from the fetal to the early neonatal period, left
ventricular (LV) output changes. The twofold increase in LV output at 1 hour of age
results primarily from increased stroke volume associated with elevated left ventricular
end diastolic diameter  (LVEDD) and fractional shortering (FS) (Agata et al. 1991). In
healthy term infants, the increase in LV end-diastolic volumes postnatally seems to
depend on changes in the ductus arteriosus flow (Agata et al. 1994; Kishkurno et al.
1997). In term neonates, growing stroke volume produces a 27% increase in cardiac
output, whereas heart rate does not change significantly. Mean blood pressure increases
by nearly the same extent as cardiac output during the first 5 days after birth, but the
vascular resistance does not change (Mandelbaum et al. 1991). This neonatal elevation in
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cardiac output can be attributed to the combined effects of increased heart rate, venous
return, end-diastolic volume, and inotropy in association with the effects of birth (Agata
et al. 1991; Mandelbaum et al. 1991; Walther et al. 1993; Kishkurno et al. 1997). 
Normal standards for cardiac output in neonates increase linearly with advancing birth
weight and gestational age. For clinical use, 325 ml/min/kg and 200 ml/min/kg can serve
as the upper and lower limits of normal (Walther et al. 1985a). 
Circulating catecholamine levels are elevated in the neonate (Lagercrantz and Bistoletti
1973; Lagercrantz 1996); even stressed neonates respond well to exogenous
administration of inotropic agents and can increase their cardiac output. However, the
newborn may respond less well to states that require a further increase in output or to
diseases that blunt the effects of these mechanisms. In the days following birth, heart rate
decreases and cardiac output falls. These postnatal changes suggest that the heart is
acquiring greater functional reserves (Lopez et al. 1997; Pladys et al. 1997). 
2.3. ECHOCARDIOGRAPHIC STUDIES
2.3.1. Fetal Examinations
Anatomy of the fetal heart
Four or five transverse sections through the abdomen and chest of the fetus may be
sufficient to provide a full examination of the fetal heart. The first view shows the
abdominal situs with the aorta to the left of the spine and the inferior caval vein anterior
to the right. The normal fetal stomach and heart lie on the left side. The four-chamber
view illustrates the chambers of the heart with the left atrium in front of the spine and the
right ventricle below the sternum. The image of the outflow tracts shows the aorta arising
centrally in the heart from the left ventricle, and the pulmonary trunk arising from the
anteriorly placed right ventricle and crossing to the fetal left over the ascending aorta.
The great vessels should be imaged up to the connection of the ductal arch and
descending aorta. The short axial view shows the anteriorly positioned ductal arch and
the transverse aortic arch. Some additional views are useful in order to make a full
diagnosis in cases of abnormality: coronal view (AV-valve anomalies), sagittal views (the
superior and inferior caval veins draining into the right atrium), and the aortic arch-view
(Gardiner 2001; Bronshtein and Zimmer 2002).
Fetal flow velocities
In the normal fetal heart, the maximum flow velocities increase with gestation at both the
aortic and pulmonary valves (Kenny et al. 1986; Rizzo and Arduini 1991). Waveforms in
ductal systolic velocities are the highest velocities in the fetal heart (Huhta et al. 1987).
Abnormally high ductal flow velocities may reflect a constriction of the fetal duct, or
increased volume in the right heart (Huhta et al. 1987; Tulzer et al. 1991b). However, the
shape of the ductal waveform differs: with increased flow, the pattern is pulsative with a
rapid decrease after peak velocity, whereas in ductal constriction, the velocity slowly
decreases from its maximum to end-diastole. 
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An assessment of fetal cardiac function can be made using traditional M-mode to provide
information on wall thickness and the ventricular shortening fraction. In the M-mode,
simultaneous recordings of the atrial wall and ventricular wall are possible and rhythm
disturbances visible (Carvalho et al. 2001). 
FETAL CONGESTIVE HEART FAILURE
Fetal congestive heart failure is a situation leading to inadequate tissue perforation and
results in a series of complex reflexes and adaptations to improve forward flow or direct
it to vital organs. This clinical state in the fetus can be characterized by at least four types
of findings obtained during ultrasonographic examination: redistribution of cardiac
output, cardiomegaly, abnormal venous Doppler, and abnormal myocardial function. Any
of these may occur before fetal hydrops. Treatment of congestive heart failure is based on
its etiology. Heart failure can be seen during disorders of cardiac rhythm, abnormal
peripheral impedances, anemia, valve regurgitation, or myocardial dysfunction (Gardiner
2001; Huhta 2004). Cardiac function can be visualized with 2D echocardiography and M-
mode measurements.  Total cardiac dimensions measured by the four-chamber view as
the distance between the anterior wall of the right ventricle and the posterior wall of the
left ventricle at the level of both atrioventricular valves- have been shown to increase
beyond the standard deviation of the normal value in fetal cardiac failure (Kato et al.
1987).
2.3.2. Neonatal Examinations
Postnatally, a two-dimensional echocardiograph with standard projections permits a
comprehensive and precise anatomic study of the heart. 
The M mode allows evaluation of the left and right ventricular dimensions, the thickness
and motions of the ventricular walls, left ventricular ejection fraction, and fractional
shortening. These measurements are usually made from long- or short-axial parasternal
views (Folland and Parisi 1983).
Cardiac output measurements are based on the velocity of blood flow in the aorta, with
the area under the velocity curve integrated manually or automatically. The diameter of
the aorta is measured by echocardiography in the parasternal long-axial view, and the
cross-sectional area calculated. The product of the velocity curve integral and the cross-
sectional area provides the stroke volume. Cardiac output is calculated by multiplying
stroke volume by heart rate. When the heart rate varies, averaging stroke volume over
several cardiac cycles is necessary (Walther et al. 1985b; Eriksen and Walloe 1990).
The reliability of the measurements has been discussed: within measurements made by
the same investigator reproducibility is good. Accurate assessment of blood flow velocity
requires the Doppler beam to be aligned with the long axis of the aorta, and any deviation
will result in an underestimation. In practice, providing the angle is less than 15º, the
error will be less than 3%. The site generally used has been suprasternal (Hudson et al.
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1990b). The main limitation of this technique seems to be in accurate measurement of
aortic diameter, in which a small error produces a relatively large error in calculations of
cardiac output (Hudson et al. 1990b; Tibby et al. 1997).
Doppler echocardiography enables measurements of blood flow through the
atrioventricular and semilunar valves and in the veins and arteries. It allows assessment
of the duration of patency and morphological changes in the ductus arteriosus (Hiraishi et
al. 1987; Evans and Archer 1990; Walther et al. 1993). The pattern of ductal flow can be
studied by continuous and pulsed wave Doppler. Decrease in pulmonary vascular
resistence increases left-to-right shunting across the ductus arteriosus, and the direction
and flow velocities of this ductal shunting can aid in measurement of pulmonary arterial
pressure (Kääpä et al. 1992; Seppänen et al. 1994). In unidirectional left-to-right ductal
shunting, systolic pulmonary pressure is calculated by subtracting the ductal Doppler
velocity at the peak systole from the corresponding systemic blood pressure.  Tricuspidal
regurgitation can also be used for measurement of pulmonary artery pressure: the
Bernoulli equation (P = 4V2; v=blood flow velocity in tricuspidal regurgitation) can be
appied to assess the drop in pressure from the right ventricle to the right atrium in systole
(Skinner et al. 1991; Skinner et al. 1996). 
2.4. DETECTION OF CARDIAC ANOMALIES
The incidence of congenital heart disease in screening cases with no risk factors and in
those with maternal risk factors is low (7 per 1000) and similar to the expected overall
incidence in the general population of 8 per 1000 live births in the general population
(Strumpflen et al. 1996).
In a low-risk population, most cardiac lesions detected antenatally are found at a routine
18- to 20-week scan (Kitchiner 2004). For patients at increased risk for congenital heart
disease, an initial scan to exclude major malformations should be performed by the fetal
cardiology expert at 12 to 14 weeks, with a follow-up at about 20 weeks to detect minor
defects and lesions that may become evident later (Allan 2003).  Some evidence exists
that an early examination at 14 to 16 weeks of gestation is effective in finding cardiac
anomalies even in low-risk pregnancies (Bronshtein and Zimmer 2002; Comas et al.
2002; Huggon et al. 2002).
The course of a malformation in fetal life is often different from what would be expected
from postnatal experience. Incidence is increasing for fetal loss in fetuses with a
chromosome defect, with Ebstein`s anomaly, tetralogy of Fallot, and a common arterial
trunk. Of spontaneously aborted fetuses with congenital heart defects, 57% display major
chromosomal anomalies. Risk for fetal loss is very high in fetuses with isomerism of the
left atrial appendages, particularly when this involves the combination of an
atrioventricular septal defect with complete heart block (Allan and Sharland 2000). Some
anomalies are never or almost never seen after the fetal period: absent pulmonary vein
syndrome, ectopia cordis, and aorta-left ventricular tunnel (Allan and Sharland 2000).
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In the human embryo, a functional pumping tube is achieved as early as 3 weeks after
conception. A fully septated heart has developed at about 8 weeks post ovulation. At that
time, serious septation defects like atrioventricular septal defects have developed.
Remodeling of the ventricular trabeculae into a right and a left ventricular type and the
formation of fibrous atrioventricular and semilunar valve leaflets is achieved by about 14
to 16 weeks (Gittenberger-De Groot et al. 2000).
The etiology of congenital heart disease is currently the focus of intense research. Recent
epidemiological and familial studies suggest that specific genetic influences may be more
important than previously recognized, and that certain malformations are more likely to
have a stronger genetic component (Raymond et al. 1997; Tometzki et al. 1999). The
techniques of molecular genetics are becoming increasingly useful for the study of
familial congenital heart disease. A number of specific genes are now implicated in the
pathogenesis of congenital cardiovascular malformations in humans (Table 1.) (Lacro
2000). Recurrence risk projections should be based on the specific congenital heart defect
involved as well as the genetic and teratogenic history in an individual family or
pregnancy. A common genetic defect or pathogenetic mechanism may cause several
apparently different forms of congenital cardiovascular malformations. For example,
chromosome 22q deletions cause a variety of conotruncal malformations and aortic arch
anomalies (Nora 1993).
2.4.1. Fetal Screening
Specific factors identified as increasing the mothers risk of carrying a fetus with
congenital heart anomalies are a family history of congenital heart disease, coexisting
maternal disease (diabetus mellitus, collagen vascular disease, or phenylketonuria), or
exposure to teratogens such as alcohol (Strumpflen et al. 1996).
Chromosomal and extracardiac anomalies are often connected with cardiac anomalies.
Chromosomal abnormality occurs in 30 to 40% of infants with congenital heart disease
diagnosed in-utero (Kitchiner 2004).  In newborn infants, trisomy 21, 18, and 13 and
Turner syndrome account for up to 10% of congenital heart diseases (Simpson and Marx
1994). Of infants with Downs syndrome, 50% have cardiac anomalies including
atrioventricular canal defects, ventricular septal defects, and tetralogy of Fallot.
Congenital heart disease is present in virtually all fetuses with trisomy 18 and in 90% of
fetuses with trisomy 13; 35% of females with Turner syndrome will have cardiac
anomalies such as coarctation of the aorta and hypoplastic left heart syndrome. Based on
these statistics, when a nonlethal chromosomal abnormality is diagnosed by genetic
testing, a careful fetal echocardiogram should follow (Lutin et al. 1999), and if congenital
heart disease appears prenatally, the fetus should also be karyotyped (Allan et al. 1991).
The major extracardiac anomalies (central nervous system, urogenital system,
gastrointestinal system, abdominal wall, labiopalatoschisis, and extremities) are often
associated with cardiac anomalies (Fesslova et al. 1999; Kitchiner 2004). The prevalence
of noncardiac anomaly with a major congenital heart defect is 15 to 40% in newborns
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with a normal karyotype. No specific cardiac defect seems to be associated with
extracardiac anomalies, except for a possible relation between spleen anomalies and
endocardial cushion defects (Pradat 1997). 
Table 1.  Known cardiovascular gene defects in humans
Structural defects Gene defects
Marfan syndrome Fibrillin gene mutations, chromosome
15q21, 5p23.31
Familiar supravalvar aortic stenosis Elastin gene mutations, chromosome
7q11.23
William`s syndrome 1-2 megabase deletion including elastin
and other genes, chromosome 7q11.23
Alagille`s syndrome, tetralogy of Fallot JAGI (Jagged 1), chromosome 20p12
Rendu-Osler-Weber syndrome Endoglin, chromosome 9q33-p4
Ehlers-Danlos syndrome COL3Aa1 gene, Type III collagen,
choromosome 2q31-q2
Holt-Oram syndrome Chromosome 12q2, TBBX5,
a transcription factor
Noonan`s syndrome Chromosome 12q
Ellis-van Creveld syndrome Chromosome 4q16
Familial totally anomalous pulmonary
venous connection
Chromosome 4p13-q12
Atrioventricular canal defects Chromosome 21q22.2-21q22.3
Chromosome 8 deletion
Chromosome 1p31-p21
Conotruncal defects /
CATCH 22 syndrome
Deletion on chromosome 22q11, deletion
on chromosome 10p13
Heterotaxy ZIC3, transcription factor, chromosome
Xq24-q27.1, chromosome 6
First-trimester nuchal translucency (NT) measurement is widely used at approximately
10 to 14 weeks of pregnancy as a screening method for fetal chromosomal anomalies and
cardiac abnormalities (Taipale et al. 1997; Haak et al. 2002; Chasen et al. 2003).
Increased nuchal translucency thickness is thought to be the result of subcutaneous edema
in the nuchal region. Many have reported an association between increased NT and an
increased rate of spontaneous fetal loss (for fetal nuchal translucency thickness of  >
5mm, a rate of 13%) and genetic syndromes and a high prevalence (15%) of anomalies,
among which cardiac defects are the most common (Nicolaides et al. 1994; Pandya et al.
1995; Snijders and Smith 2002).  In a meta-analysis of 16 studies of chromosomally
normal fetuses with increased NT above the 95th centile of the normal range, a cardiac
defect was evident in 4% (Souka et al. 1998). When also minor anomalies like silent
ductus arteriosus and small atrial septal defects were recorded postnatally, the prevalence
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was as high as 8% (Hiippala et al. 2001). The probability of heart defect in
chromosomally normal fetuses increases with growing NT thickness (5.3% at 3.9 mm
and 24% with thickness of 6 mm or more) (Galindo et al. 2003). In the study by Hyett et
al., 55% of major cardiac anomalies were associated with increased NT thickness at 10 to
14 weeks of gestation (Hyett et al. 1999).
2.4.2. Accuracy of Prenatal Echocardiography
            Information on the accuracy of perinatal echocardiographic diagnosis is accumulating. If
only a four-chamber view is used, the detection rate of anomalies is 30 to 50% in low-risk
pregnancies (Kitchiner 2004). If the out-flow tracts are also visualized, the detection rate
of anomalies increases to 78 to 83% (Simpson and Marx 1994; Allan 1996; Carvalho et
al. 2002). The diagnoses of complex cardiac abnormalities in utero have correlated
closely with the anatomic findings during postpartum ultrasound or cardiac
catheterisation, or during autopsy (Leung et al. 1999; Haak et al. 2002). The prenatal
detection rate of congenital heart disease continues to increase as obstetric screening for
cardiac malformations becomes more widespread (Brick and Allan 2002). 
  
Detection rates for specific cardiac lesions are wide-ranging; from 5 to 44% for isolated
ventricular septal defects, 50% for univentricular heart or hypoplastic left heart
syndrome, to 87% for atrioventricular septal defects (Kirk et al. 1997; Stoll et al. 1998;
Klein et al. 1999). In publications reporting the highest detection rates, 78% of the
malformed fetuses were detected prenatally, with nearly 60% being detected before 22
weeks of gestation (Allan 1996; Tometzki et al. 1999). In many studies, however, the
detection rate in the screening groups without risk factors has only been from 3% to 13%
(Buskens et al. 1996; Allan 1997; Stoll et al. 1998). 
False-positive diagnoses are limited to two types: ventricular septal defects and aortic
coarctation (Perolo et al. 2001). Small septal defects and minor valve abnormalities
frequently lie outside the resolution and limits of detection of the ultrasound equipment.
Because atrial septal defects and arterial ducts form part of the normal fetal circulation,
they are therefore not detectable antenatally (Kitchiner 2004).
The need for combining expertise in the areas of anatomical and physiological
assessment has created a new speciality; perinatal cardiology, a merger of pre- and
postnatal management, working with both pre- and postnatal cardiac diagnosis and
treatment (Huhta 2004). 
2.4.3.  Outcome of Structural Heart Disease
Overall, the outcome of structural heart disease detected prenatally is poor. Smith et al.
reported that the figure for infants prenatally diagnosed with cardiac defects surviving the
postnatal period was only 38%(Respondek et al. 1994). In the Italian study by Fesslova et
al, 43% of the infants died postnatally, and only 45% survived more than 18 months,
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whereas in the study by Brick and Allan, the survival rate was 60%. Nevertheless, there is
an improvement in survival for each calendar year, especially in the hypoplastic left heart
syndrome and in the group with atrioventricular septal defects (Fesslova et al. 1999;
Brick and Allan 2002). Surgical mortality for most congenital heart disease is less than
5%, but this is not reflected in the outcome of antenatally diagnosed lesions. The more
severe end of the spectrum of congenital heart disease is diagnosed antenatally, and these
infants have a much higher incidence of chromosomal and extracardiac abnormalities
(Kitchiner 2004).
The spectrum of heart defects among spontaneously aborted fetuses is similar to that
among the liveborn (Ursell et al. 1985). Thus, 57% of those spontaneously aborted with
congenital heart defects show major chromosomal abnormalities. According to the
literature, 11.9% of fetuses with cardiac defects die in utero (Fesslova et al. 1999).
During fetal life, intercirculatory connections (the foramen ovale and ductus arteriosus)
play a key role in equalizing intracardiac and great artery pressures.  Any rise in left atrial
pressure results in a reduction in right-to-left atrial flow through the foramen ovale.
Premature restriction or closure of the foramen ovale reduces left heart flow and may
result in left heart hypoplasia (Hornberger et al. 1995). With prenatal restriction, or
complete premature closure of the foramen ovale, flow is diverted away from the left
atrium and left ventricle. This has little effect on systemic perfusion in utero, because the
right ventricle continues to eject the systemic circulation via the ductus arteriosus, and
pulmonary blood flow is relatively minimal. However, at birth, pulmonary blood flow
increases, as does pulmonary venous return to the left atrium, resulting in marked
elevation of pulmonary venous pressure (Rychik et al. 1999). With hypoplastic left heart
syndrome or with transposition of the great arteries, a restrictive foramen ovale with or
without constriction of the ductus arteriosus may be fatal in the early neonatal period
(Maeno et al. 1999). 
The prenatal detection of left and right heart obstructive lesions and the evolution of these
heart defects during the second half of gestation are nowadays well documented.
Hornberger et al. (1995) have shown that in the presence of obstructive lesions, growth of
heart structures through the second half of pregnancy was reduced, resulting in
progression of the severity of left or right heart hypoplasia. They found heart growth to
decrease the most through the second and third trimesters in fetuses with a severe
obstruction already at mid trimester. However, when severe outflow obstruction
developed late in gestation or when there was only mild ventricular inflow or outflow
obstruction, the in-utero growth of heart structures was normal or only mildly reduced
(Hornberger et al. 1995). Although the specific mechanism of impairment of the left or
right heart growth in the presence of obstruction remains unknown, it is most likely the
effect of several structural and hemodynamic abnormalities that result in a reduction in
blood flow through the mitral or tricuspidal valve, the ventricles, and the aorta or
pulmonary artery (McCaffrey and Sherman 1997; Simpson et al. 1997; Daubeney et al.
1998). A severe semilunar valve obstruction leading to impaired growth and compliance
rarely causes fetal death (Simpson and Sharland 1997).
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In the fetuses with structural heart disease, evaluation of chromosomal abnormalities,
extracardiac anomalies, and fetal hydrops is important because these findings are
associated with a poor prognosis (Respondek et al. 1994; Wladimiroff et al. 1995). Of
fetuses referred for assessment of nonimmune hydrops, 20 to 40% show evidence of
cardiac disease (Simpson and Marx 1994). Several studies have reported a high rate of
chromosomal abnormalities (up to 20%) and extracardiac anomalies (up to 32%) with
congenital heart defects (Brick and Allan 2002). The combined ventricular output in
fetuses with congenital heart disease is significantly lower in utero than that in matched
control fetuses with normal cardiac anatomy (Lutin et al. 1999). 
2.5.  INTRAUTERINE INTERVENTIONS 
The primary aim of prenatal intervention in cardiac heart disease is to reverse the
pathological process and to preserve cardiac structure and function, thereby preventing
postnatal disease. A secondary aim of prenatal intervention is to modify the severity of
the disease to enhance postnatal surgical outcome.
Balloon dilatation of the aortic or pulmonary valve has been performed in late-gestation
human fetuses with failing left or right ventricles, but the technical success of such fetal
valvuloplasty is currently poor, and the indications for fetal intervention limited. If
antegrade flow could be established earlier in gestation, perhaps normal or near-normal
left or right heart growth and function would be ensured (Simpson and Sharland 1997;
Daubeney et al. 1998; Kohl et al. 2000; Kohl 2002; Tulzer et al. 2002; Tworetzky and
Marshall 2003).
2.6. IMPACT OF FETAL ECHOCARDIOGRAPHY ON POSTNATAL
OUTCOME
Increasing prenatal detection of cardiac defects has led to a reduction in birth prevalence
of difficult lesions.  This reduction has been greatest in lesions with univentricular
physiology (Brick and Allan 2002).  Increased fetal detection rates have led to an increase
in neonates with minor cardiovasvular defects (Wren et al. 2000).  Birth prevalence of
hypoplastic left heart syndrome and pulmonary atresia with intact ventricular septum has
been reduced; in the United Kingdom 61% of the fetuses with prenanatal diagnoses of
pulmonary atresia with intact ventricular septum were being terminated (Daubeney et al.
1998). 
Detection of congenital heart disease before delivery is clinically important, due to the
potential life-threatening implications at birth. Early detection of cardiac anomalies offers
the possibility of termination of pregnancy or of antenatal care, delivery, and immediate
postnatal care within the same institution (Perolo et al. 2001; Verheijen et al. 2003).
Instant postnatal care prevents lactate increase in the preoperative period and may reduce
the risk for cerebral damage and result in better condition during surgery (Verheijen et al.
2002).
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Prenatal diagnosis of a ductus-dependent heart defect results in avoidance of
hemodynamic compromise, reduced organ dysfunction, and reduced surgical delay.  Pre-
delivery transport of fetuses with suspected critical left ventricular outflow tract
obstruction to a neonatal cardiac surgical center can result in improved neonatal condition
and may also improve overall survival (Chang et al. 1991). Indeed, some patients with
severe heart defects not diagnosed prenatally may be discharged home, and some of these
infants may die at home before any return to the hospital. Early identification of a heart
defect allows for planned delivery at a site where neonatology, pediatric cardiology, and
congenital heart surgery services are readily available.
In biventricular heart defect, prenatal diagnosis improves survival, and postoperative
mortality is significantly lower (Copel et al. 1997; Bonnet et al. 1999). The clinical
condition (including metabolic acidosis and multiorgan failure) at arrival in the
cardiology unit in the group of patients that have been diagnosed postnatally is worse
(Copel et al. 1997; Eapen et al. 1998; Bonnet et al. 1999; Verheijen et al. 2001). 
In most studies, prenatal diagnosis of univentricular heat defect has not reduced
postoperative mortality or length of hospitalization (Copel et al. 1997; Eapen et al. 1998;
Verheijen et al. 2001), although it minimizes preoperative acidosis. In a recent study by
Tworetzky et al., those patients with a prenatal diagnosis of hypoplastic left heart
syndrome did have a lower incidence of preoperative acidosis, tricuspid regurgitation,
and ventricular dysfunction and were less likely in need of inotropic medications.
Prenatal diagnosis was associated with better survival rates after first-stage surgery. The
only risk factor for early mortality was postnatal diagnosis (Tworetzky et al. 2001). 
Among patients with congenital heart lesions, prevention of metabolic acidosis may be
associated with improved long-term outcome and prevention of cerebral damage (Eapen
et al. 1998). 
Although survival rates for Norwood-type programs for hypoplastic left heart syndrome
are currently 60 to 70% over the first 2 to 5 years of life, at the point of prenatal
detection, overall survival rate is much lower. In two recent studies, only 36 out of 87 and
50 out of 174 cases with fetal diagnoses of hypoplastic left heart syndrome underwent
surgery (Brackley et al. 2000; Andrews et al. 2001).
2.7.  FETAL ARRHYTHMIAS: PREVALENCE, TREATMENT, AND OUTCOME
Fetal cardiac arrhythmias are defined as any irregular fetal cardiac rhythm or any regular
rhythm at a rate outside the reference range of 120 to 160 beats/min (Copel et al. 2000).
Increases in fetal heart rate within the physiologic range result in a decrease in ventricular
size and stroke volume but do not change ventricular output or ventricular shortening
(Kenny et al. 1987).  Heart rates greater than 200/min are uniformly abnormal and can
lead to fetal cardiac insufficiency and with resistance to therapy, even to fetal death.
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2.7.1.  Atrial Extrasystoles (AES)
Irregular fetal heart rhythm is most frequently due to the atrial extrasystoles (AES) that
account for 70 to 88% of the fetal arrhythmias (Respondek et al. 1997). 
In the vast majority of cases, AES resolve spontaneously either prenatally or early in the
postnatal period and reguire no treatment.  Multiple blocked AES can cause a ventricular
rate lower than 100 beats/min, which may simulate fetal asphyxia or atrioventricular
block (AVB). Supraventricular tachycardia (SVT) occurs in 2% of the cases with
multiple atrial ectopic beats compared to 13% of the cases with blocked atrial ectopic
beats (Simpson et al. 1997). In general, the association between AES and SVT is
approximately 1% to 2% (Kleinman et al. 1985).
These arrhythmias are usually benign and are associated with favorable prognoses;
generally, they do not influence the incidence of pre- or postnatal disease or mortality
(Respondek et al. 1997; Simpson et al. 1997; Copel et al. 2000). AES have not been
considered risk factors for cardiac anomalies. Recent reports suggest that cardiac defects
can be found in only 0.3 to 2% of fetuses with AES (Simpson and Marx 1994; Allan
1996). 
2.7.2.  Atrial Tachycardia (AT)
The most common serious dysrhythmia detected prenatally is supraventricular
tachycardia (SVT). 
Intermittent tachycardia with ventricular rates ranging from 180 to 200/min are often well
tolerated and of little clinical significance if the duration of the tachycardia is short.
Those tachycardias with ventricular rates higher than 200 are poorly tolerated even when
intermittent and can lead to hydrops (Simpson and Sharland 1997). Chronic
supraventricular tachycardia causes a rapid, reversible dilated cardiomyopathy in
humans and in animals. Ventricular end-diastolic pressure increases, and the ventricular
ejection fraction decreases. Structural alterations suggestive of myocyte injury indicate
inadequate myocardial blood flow (Krapp et al. 1997).
The majority of supraventricular tachycardias are considered re-entrant dysrhythmias and
are characterized by a fetal heart rate of more than 200 beats per minute with 1-to-1 atrial
to ventricular activity (Simpson and Marx 1994; Wren 1998). Re-entry tachycardia arises
from a circus movement of electrical energy between the atria and ventricles, involving
the atrioventricular node in one direction and an accessory connection in the other. The
heart rate is dependent on the size of the re-entry pathway and the intrinsic electronic
properties of the limbs of the circuit (Kleinman and Nehgme 2004). Atrioventricular re-
entry tachycardias account for at least 70% of cases; atrial flutter (AF) accounts for 10 to
15%. Ectopic focus supraventricular tachycardia is rare in utero, and ventricular
tachycardia is extremely rare (Meijboom et al. 1994). Atrial flutter is an arrhythmia that
also arises due to re-entry of electrical impulses around a circular pathway. The AV node
is not part of the circuit and serves only to transmit, with a variable degree of slowing or
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block, the atrial flutter waves to the ventricle. The atrial rate in atrial flutter in the neonate
is typically 300 to 400 beats/min, whereas in the fetus, atrial flutter rates may be up to
500 beats/min. 
Using M-mode, pulsed Doppler, and color-encoded M-mode echocardiographic
techniques, it is possible to relate mechanical and flow events to the timing and sequence
of electrical activation underlying these events.  If the tachycardia is associated with AV
dissociation or is sustained despite varying degrees of AV block, AV reciprocating
tachycardia cannot be the underlying electrophysiologic basis, since these tachycardias
are characterized by 1:1 synchrony between atrium and ventricle. When there is some
degree of AV block (atrial rate higher than ventricular rate), intra-arterial re-entry
tachycardia or atrial flutter is possible. The majority of clinically significant tachycardias
are AV reciprocal tachycardias (Jaeggi et al. 1998b). 
Measurement of ventriculo-atrial time intervals may be helpful in optimizing
management. A long ventriculo-atrial supraventricular tachycardia is reported to
associate with an increased risk of mortality and morbidity. This type of tachycardia,
relatively rare in the pediatric age group and in fetuses, is usually unresponsive to most
antiarrhythmic drugs and has a high recurrence risk after birth. Class III agents are the
potential drugs of first choice. In contrast, a short ventriculo-atrial time-interval
tachycardia responds to most antiarrhythmic drugs, and the conventional drug protocol
can be applied, with digoxin as the drug of first choice (Jaeggi et al. 1998b; Fouron et al.
2003). 
The majority of fetuses with SVT have structurally normal hearts; however, the presence
of a structural defect or intracardiac rhabdomyoma is an important part of the prediction
of fetal and neonatal outcome (Gow and Hamilton 1991). Although SVT has not been
associated with congenital heart disease, in 5% to 10% of the cases, structural cardiac
abnormalities appear and make the outcome worse (Simpson and Sharland 1998). 
In a recent retrospective review of 126 fetuses with atrial tachycardia (AT), 83% had
SVT and 17% AF. By the time of the diagnoses, close to 40% of fetuses with AT had
evidence of hydrops (Simpson and Sharland 1998). In some series, AF is associated with
a higher risk for decompensation and hydrops than is SVT (Reed et al. 1987) but in
others, it has been better tolerated, perhaps because the variable AV conduction results in
lower ventricular rates (Azancot-Benisty et al. 1992). Kleinman and Copel noted a high
incidence of cardiac failure and a poor outcome in fetuses with atrial flutter. However,
their study did include fetuses with structural heart disease.
The long-term prognosis of AF may be life-threatening because of the difficulty of
treatment and the need for several drugs (Kleinman et al. 1985; Azancot-Benisty et al.
1992). Duration of fetal tachyarrhythmia may influence occurrence of cardiac failure; in
experimental permanent rapid atrial pacing, hydrops has developed as early as 15 hours
after initiation of pacing (Gow and Hamilton 1991).
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Fetal AT has been successfully treated with a variety of antiarrhythmic agents including
digoxin, flecainide, propanolol, sotalol, verpamil, adenosine, guanidine, procainamide,
and amiodarone, with the digoxin and flecainide the most commonly used. Digoxin as a
single therapy is not successful in restoring sinus rhythm in all fetuses with atrial flutter
or in hydropic fetuses (Frohn-Mulder et al. 1995; Jaeggi et al. 1998a; Krapp et al. 2003).
Flecainide and sotalol have been reported to have potential proarrhythmic properties
(Gow and Hamilton 1991).
When a fetus is hydropic or less than 36 weeks of gestation, maternal drug treatment is
most appropriate. Surgical delivery of a nonhydropic fetus with tachycardia in the
presence of fetal lung immaturity is inadvisable. The experience has led to high mortality
and incidence of complications with prematurity. Reports even exist of prior cerebral
complications in utero (Sonesson et al. 1996). Control of the arrhythmia in utero is
preferred, to provide the fetus with a better neonatal start (Meijboom et al. 1994).
Prenatal control of AT is associated with an improved rate of survival. The majority of
the non-hydropic fetuses (60-80%) convert to sinus rhythm after oral digoxin treatment
only. When this fails, substitution of digoxin by flecainide has resulted in control`s being
established in 83 to 92% of cases (Frohn-Mulder et al. 1995; Ebenroth et al. 2001;
Jouannic et al. 2002; Krapp et al. 2002). Flecainide has been proven effective also in
hydropic fetuses, with 43 to 66% converting to sinus rhythm (Frohn-Mulder et al. 1995;
Ebenroth et al. 2001). In a recent study of flecainide by Krapp et al., conversion into
sinus rhythm was achieved by 19 of 20 fetuses (of which 15 were hydropic) with no
complications (Krapp et al. 2002).
Because of the potential proarrhythmic dangers of flecainide, however, the search for
new and possibly better drugs has continued. In a study by Oudijk and al. (2000), 20
patients were treated with sotalol, and 7 of 12 non-hydropic fetuses were converted to
sinus rhythm but only 2 of 8 hydropic with sotalol as a single therapy. Efficacy of sotalol
as a single therapy was 40% in the SVT group; in the AF group, 50% reverted to sinus
rhythm. After the addition of digoxin, another 20% in the SVT group and 30% in the AF
group reverted to sinus rhythm. Because of this unsatisfactory conversion rate (60%) and
the three fetal deaths in the SVT group, the authors suggest limiting the use of sotalol to
those cases in which other treatments have failed (Oudijk et al. 2000). In a study by
Sonesson et al., control of SVT was achieved in 10 of 14 fetuses (6 of 8 with hydrops)
with a combination of sotalol and digoxin (Sonesson et al. 1998).
Direct fetal therapy with amiodarone has been advocated, to prevent the problems of
transplacental transfer of antiarrhythmic drugs. Forms of direct therapy include: injection
into the umbilical vein or intramuscularly, intraperitoneal, or intracardiac injections, or a
combination of methods (Hansmann et al. 1991; Flack et al. 1993). Orally administered
amiodarone has been effective in restoring sinus rhythm also in hydropic fetuses
(Jouannic et al. 2003; Strasburger et al. 2004).
Earlier studies demonstrated that 44% of children with fetal SVT and 64% of cases with
fetal AF would suffer a recurrence of arrhythmia after birth (van Engelen et al. 1994).
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The expected history of AT is, however, spontaneous resolution during the first year of
life (Benson et al. 1987; Naheed et al. 1996). Some units choose to observe initially and
treat only those newborns that suffer a recurrence of tachycardia. In other units,
antiarrhythmic treatment is given prophylactically for at least 6 months before any
attempt to withdraw the treatment (Simpson and Sharland 1998). Neurological morbidity
has been reported to be relatively low, 1.6% in the study by Simpson and Sharland, with
127 fetuses, and 2 of  the 20 in Oudijk et al. (2000).
2.7.3  Atrioventricular Block  (AVB)
Transplacentally mediated maternal anti-Ro (SS-A) and anti-La (SS-B) antibodies cause
fibrous replacement of the conducting tissue (Schmidt et al. 1991; Eronen et al. 2001),
and are associated with autoimmune diseases such as lupus erythmatosus and Sjögren`s
syndrome. Some 70 to 80% of fetuses with autoantibody-induced heart block have,
however, clinically asymptomatic mothers without any diagnosis of autoimmune disease.
These antibodies can also cause an inflammatory myocarditis and myocardial fibrosis
revealing itself as fetal hydrops or pericardial effusion (Groves et al. 1995). In addition,
late-onset postnatal cardiomyopathy with fatal outcome has occurred (Eronen et al.
2000).
Risk for complete congenital heart block is 5% for mothers with anti-Ro antibodies but
increases to around 25% in pregnancies of women with previously affected children
(Groves et al. 1995). The early signs of developing complete congenital av-block can be
visible in fetus between 18 to 24 weeks of gestation. In affected fetuses, atrioventricular
time intervals are longer and heart rates slightly lower than in normal fetuses. A first-
degree block may progress to a complete block before term but it may also normalize.
Fetuses with normal atrioventricular time intervals at 18 weeks of gestation usually have
normal conduction after birth (Sonesson et al. 2004).
Most fetuses with congenital complete heart block and normal cardiac anatomy will
survive until term and throughout the neonatal period if their ventricular escape rate is
higher than 55/min. If the ventricular escape rate falls below 55/min or if additional
cardiac malformations are present, fetal hydrops from cardiac failure is likely to occur
(Gow and Hamilton 1991; Kohl 2002). Increased mortality risk is associated with fetal
hydrops and endocardial fibroelastosis, and with delivery before 32 weeks of gestation
(Jaeggi et al. 2002).
The most common form of heart defect with AVB is left atrial isomerism (59%), with
cTGA being the second largest group (24%) (Schmidt et al. 1991). Altogether, 83% of
the cases die in utero or in infancy, in contrast to the prognosis for fetuses with isolated
AVB, of whom 85% survive.
In utero, therapeutic trials with sympathomimetics, digitalis, and steroids have produced
no clear evidence of the effectiveness of in-utero medication. Some data show that
salbutamol can be effective in the treatment of fetal complete heart block, so its use
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should be considered in patients with evidence of deteriorating cardiac function (Groves
et al. 1995). Steroids may treat the associated myocarditis, but they may also treat
inflammatory exudates and improve cardiac conduction (Rosenthal 2000).
2.7.4. Sinusbradycardia  (SB)
Persistent fetal SB with 1:1 atrioventricular conduction is a rare condition and has been
reported in connection with central nervous system abnormalities, maternal treatment
with beta blockers, excessive vagal tone, hydrops, and intrauterine growth retardation
(Hofbeck et al. 1997). Sinusbradycardia has also been associated with complicated heart
defects with absence of or hypoplasia of the sinus node (Schmidt et al. 1991) and
wandering pacemaker (Maeno et al. 2003).  Hofbeck et al. present a series of 9 fetuses
with long QT syndrome. Seven fetuses had persistent sinus bradycardia without
ventricular arrhythmias, and two fetuses presented frequent runs of ventricular
tachycardia and intermittent bradycardia. The latter two, despite treatment with
propranolol and pacing, died on the first day of life (Hofbeck et al. 1997).
2.7.5.  Ventricular Extrasystoles (VES)
Ventricular tachycardia is rare. The prognosis in the few reported cases has been poor.
The fetal ventricular extrasystoles are associated with cardiac tumors, or with complex
defects with chromosomal abnormalities (van Engelen et al. 1994).
2.8.  FETAL FUNCTIONAL HEART DISEASE
The etiology of fetal functional heart disease is very complex. A heterogeneous group of
fetal pathologies result in the same kind of cardiac decompensation with fetal hydrops,
pericardial effusion, or cardiomyopathy. Mortality in fetal hydrops is as high as 64%; in
earlier manifestations of cardiac insufficiency, the mortality has been equal to or less than
25% (Respondek et al. 1996). Postnatally,  prognosis will depend on whether the insult is
reversible and whether periods of ischemia and / or brain injury  occurred. 
2.8.1.  Placental Insufficiency and Growth-Restriction
Fetal investigations with Doppler techniques have demonstrated that chronic fetal distress
is often associated with hemodynamic changes in the fetal and umbilical blood
circulation. The fetal circulatory response to hypoxemia and asphyxia is a rapid
centralization of blood flow in favor of the brain, heart, and adrenals and at the expense
of almost all peripheral organs, particularly of the lungs, skin, and scalp (Räsänen et al.
1989; Jensen et al. 1999).
Fetal hypoxia may be induced by a number of mechanisms, but the general fetal
cardiovascular response is similar. An acute severe onset of hypoxia will not permit the
development of compensatory mechanisms, but mild hypoxia of gradual onset may allow
time for redistribution of the circulation (Rudolph et al. 1981).
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Redistribution of blood with the highest oxygen saturation, which comes from the
placenta via the umbilical veinductus venosusforamen ovaleleft heart pathway, is
designed to maintain sufficient oxygen delivery to the myocardium and brain. Flows to
certain vital organs increase markedly: flow to the myocardium rises to about 250% of
normal values in animal models. The fetus is unable to respond to hypoxia by elevating
heart rate to raise cardiac output. In mild hypoxia, the fetus develops bradycardia with no
changes in cardiac output, but with severe asphyxia associated with metabolic academia,
fetal cardiac output falls (Hecher et al. 1995).
In chronic placental insufficiency and fetal growth retardation, blood flow velocities in
the descending aorta are decreased. Left ventricular function appears to remain normal,
but the fetuses develop relative right ventricular dysfunction with increasing right
ventricular dimensions in relation to the left (Räsänen et al. 1989; Mäkikallio et al.
2002a). Delivery of oxygen to the brain is preserved as long as net flow through the aortic
isthmus is antegrade. If the flow is retrograde, oxygen delivery falls, which may lead to
an unfavorable neurodevelopmental outcome (Fouron et al. 2001). Intrauterine growth
retardation is associated with profound fetal circulatory changes, as demonstrated in
Doppler blood flow studies of the growth-retarded fetus with a reduction in diastolic
velocities of the descending aorta and umbilical artery and a corresponding increase in
pulsatility index. This indicates an increased resistance in the placental vascular bed (Ley
et al. 1997; Ferrazzi et al. 2002). Studies correlating Doppler changes in the fetal
circulation and perinatal outcome suggest that longitudinal Doppler surveillance may
play a role in preventing perinatal death. Doppler changes occurring in the ductus
venosus and aortic outflow tracks are late indicators of fetal distress associated with
increasing fetal lactacidemia, circulatory collapse, and intrauterine death (Rizzo et al.
1996; Ferrazzi et al. 2002).
Fetuses of chronically hypertensive patients are at increased risk for intra-uterine growth
restriction, abruption placenta, and death. Risk for these complications is directly
correlated with degree of blood pressure elevation (Neerhof 1997). In severe maternal
hypertension, increased peripheral and placental resistance can lead to reduced
myocardial contractility, elevated end-diastolic ventricular pressure, and heart failure
with hydrops fetalis (Rizzo et al. 1996).
FETAL DUCTAL OCCLUSION AND TRICUSPIDAL REGURGITATION
With advancing gestation, the blood flow velocity of the ductus arteriosus increases both
in normal and small-for-gestation-age fetuses. Factors that may affect ductal blood flow
velocities are cardiac output, ductal diameter, and fetal systemic vascular resistance.
Blood velocity at the level of the ductus arteriosus may depend on an equilibrium among
these three main factors. Prostaglandin inhibitors reduce the diameter of the ductus
arteriosus, and consequently, ductal blood velocity increases. The increased velocity in
the fetal ductus arteriosus with advancing gestational age may be a function of a relative
constriction of the ductus (Mari et al. 1996).
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In animal experiments, acute ductal occlusion significantly raises pulmonary artery
systolic and diastolic pressures and reduces the ratio of pulmonary artery flow to aortic
flow. Right ventricular end-diastolic and end-systolic diameters increase after ductal
occlusion, and the right ventricular shortening fraction decreases (Tulzer et al. 1991a) 
Because prematurity accounts for 75% of perinatal mortality, various agents have been
used to prevent premature labor. Since 1974, indomethacin has served as a tocolytic
agent. It has been related to constriction of the fetal ductus arteriosus (Eronen et al.
1991). Sulindac (a nonspecific COX-2 inhibitor) is structurally closely related to
indomethacin but is a prodrug with little or no placental transfer in animal studies
(Räsänen and Jouppila 1995).  The human placenta is permeable to sulindac but less to its
active sulfide metabolite (Kramer et al. 1995). Like indomethacin, sulindac reduces the
mean pulsatility index in the fetal ductus arteriosus (Räsänen and Jouppila 1995).
Chronic fetal ductal constriction can cause morphologic pulmonary vascular changes,
resulting in persistent pulmonary hypertension of the newborn. Autopsy studies have
demonstrated extensive hypertensive structural pulmonary vascular lesions even in
neonates who died shortly after birth (Ivy et al. 1996). 
In acute ductal occlusion, tricuspidal regurgitation develops instantly. It disappears
immediately after the occlusion is released. After chronic constriction, there may develop
degenerative myocardial changes in the right ventricular free wall and in the papillary
muscles of the tricuspidal valve (Tulzer et al. 1991a).
There exist many clinical situations other than ductal occlusion which are associated with
tricuspid valve regurgitations, for example, congenital heart defects such as Ebsteins
malformation, tricuspidal valve dysplasia, pulmonary atresia, and the atrioventricular
canal malformation, fetal arrhythmia, non-immune hydrops, cardiomegaly, and twin-to-
twin transfusion syndrome. In the normal fetal heart, the prevalence of tricuspidal valve
regurgitation is about 6% (Gembruch and Smrcek 1997; Smrcek and Gembruch 1999).
2.8.2. High Output Due to Anemia, Volume Overload, or Arteriovenous Fistula /
Teratoma
FETOMATERNAL TRANSFUSION
Spontaneous fetomaternal hemorrhage, an important cause of perinatal mortality and
morbidity (Fay 1983), may be the unexpected cause of death in as high as 14% of
unexplained fetal deaths. Presenting symptoms leading to this diagnosis are: anemia at
birth (35%), decreased fetal body movement (27%), unexpected stillbirth (12%), hydrops
fetalis (8%), fetal distress (7%), intrauterine growth retardation (3%), fetal atrial
fibrillation, and sinusoidal heart rate pattern (Laube and Schauberger 1982; Giacoia
1997).
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At birth, infants may exhibit the following conditions: central nervous system
dysfunction, respiratory distress, persistent pulmonary fetal circulation, hydrops,
hepatomegaly, cardiomegaly, or renal dysfunction (Giacoia 1997). 
TWIN-TWIN TRANSFUSION SYNDROME
Twin-twin transfusion syndrome complicates between 5 to 35% of monochorionic twin
pregnancies.  It arises as the result of vascular anastomoses between the circulation of one
twin (the donor) and the co-twin  (the recipient).  As a result the donor twin becomes
growth retarded and oliguric and develops oligohydramnion, whereas the recipient twin
becomes polyuric with hydramnious and may develop hydrops (Zosmer et al. 1994).
This transfusion syndrome is associated with an extremely poor outcome if the twin
develop hydrops. In the donor fetus, development of hydrops is associated with
worsening anemia and heart failure. The end feature in the recipient twin can also be a
generalized hydrops, reflecting volume overload. 
In untreated transfusion syndromes, perinatal mortality rate has been as high as 70%, with
similar rates in the larger and smaller twin (Sonntag et al. 1996).   Perinatal morbidity is
also significant and is due mainly to complications related to prematurity and intrauterine
growth retardation (Lopriore et al. 1995; Fesslova et al. 1998). The death of one twin
after 20 weeks` gestation may be followed by cerebral infarction in the surviving twin
(Lopriore et al. 1995; Fesslova et al. 1998).
 
Most recipient twins develop cardiac dysfunction with right ventricular hypertrophy,
dilatation, and tricuspid regurgitation in utero (Zosmer et al. 1994; Fesslova et al. 1998).
The pathogenesis of these cardiovascular manifestations remains unclear, but release of
growth factors and vasoactive peptides by the placenta to the recipient twin has been
implicated. Serial amniocenteses and endoscopic laser ablation of placental vascular
anastomoses improve outcome of affected pregnancies (Pedra et al. 2002).  A high
prevalence of congenital heart disease such as endocardial fibroelastosis, LV
hypertrophy, and right- and left-ventricular outflow track obstruction has been reported
(Lazda 1998; Karatza et al. 2002).  
TERATOMA AND ATRIOVENOUS MALFORMATIONS
Cardiovascular abnormities have been associated with hydrops fetalis in 26% of the
reported cases, with lesions that result in right atrial pressure or volume overload most
commonly the cause. Intracranial meningeal hemangioendotheliomas, teratomas, and
atrioventricular malformations have all been documented as resulting in high-output
cardiac failure (Knilans 1995).
Teratomas are the most common congenital neoplasms. Mediastinal teratomas are
uncommon and rarely result in nonimmune hydrops fetalis (Kuller et al. 1991). Large
sacrococcygeal teratomas can lead to high-output cardiac failure with dilated ventricles
maintaining a normal fractional shortening index. The teratoma acts as a large
arteriovenous fistula; hydrops fetalis indicates failure of the fetal heart to cope with this
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large volume load (Schmidt et al. 1989; Brace et al. 2000).  Fetal demise usually occurs
shortly after diagnosis of hydrops, probably related to anemia because of bleeding into
the tumor or from the tumor into the amniotic fluid (Knilans 1995).
2.8.3. Heart Failure Due to Myocardial Dysfunction
CARDIOMYOPATHIES
Of the cardiovascular diagnoses detected in utero, cardiomyopathies account for 8 to
10%. Primary fetal cardiomyopathy is etiologically a heterogenous condition which
results from intrinsic fetal pathology as well as from extrinsic factors. Intrauterine
infections can also affect the fetal heart. Hypertrophic cardiomyopathy has been
documented prenatally and postnatally in the recipient twins of pregnancies complicated
by severe twin-twin transfusion syndrome (Pedra et al. 2002). 
INFECTION
Fetal infection can involve the heart, causing myocarditis and secondary cardiac failure
due to myocardial compromise.
Fetal parvovirus infection is a well-known case of nonimmune hydrops with general
edema, ascites, pleural and pericardial effusion, and polyhydramnios. Two different
mechanisms seem to be involved in this pathophysiology of hydrops: fetal anemia and
heart failure. Myocarditis associated with parvo infection can lead to heart failure and
intrauterine death (Forestier et al. 1999; Musiani et al. 1999; von Kaisenberg and Jonat
2001).  
Congenital toxoplasmosis is an established cause of intrauterine death and a severe
neonatal disease. It may present as fetal hydrops with anemia and pericardial effusion. If
treated, the hydrops may resolve and postnatal outcome improve (Foulon et al. 1999;
Holliman 2000).
MATERNAL DIABETES
Infants of insulin-dependent diabetic mothers have an incidence of congenital
malformations three to four times as high as that of the general population. These
anomalies include defects of the neural tube, heart, urogenital system, skeleton, and
alimentary tract, and the caudal regression syndrome (Goto and Goldman 1994). Of
these, the regression syndrome has the strongest association with diabetes, occurring
roughly 200 times as frequently in infants of diabetic mothers as in other infants (Mills
1982).  The mechanism behind these anomalies has been suggested to involve a
diminished turnover of phosphoinositide or arachidonic acid, or an excess of free oxygen
radicals.
Maternal hyperglycemia may result in fetal hyperinsulinemia and asymmetric septal
hypertrophy, macrosomia, and hypoglycemia in infants. In insulin-dependent diabetes,
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the prevalence of asymmetric septal hypertrophy is about 30%, and it usually disappears
by the age of one; it is usually diagnosed in the third trimester of pregnancy, and some
evidence exists that its presence and degree relates to the quality of maternal diabetic
control (Cooper et al. 1992).  Asymmetric septal hypertrophy may serve as a useful
marker in identifying infants at risk for complications such as idiopathic respiratory
distress syndrome and persistent pulmonary hypertension.
ENDOCARDIAL FIBROELASTOSIS
Endocardial fibroelastosis, characterized by an abnormal thickening of the endocardium
of one or both ventricles, may occur with or without other cardiac anomalies (Lazda
1998). During fetal development, a dilated left ventricle is the initial stage of the
contracted hypertrophied left ventricle, with a small cavity size. An in-utero diagnosis
using fetal echocardiography can be based on increased echo density of the endocardium
and poor contractility of the ventricle (Rustico et al. 1995).  This condition can occur in
uncomplicated pregnancies, and usually results in infant death from early cardiac failure
(Veille and Sivakoff 1988; Pedra et al. 2002).
2.8.4. Noncardiac Malformations 
FETAL LUNG MALFORMATIONS
Congenital chylothorax, although an uncommon condition, is the most common cause of
pleural effusion in the fetus and the neonate (Mussat et al. 1995).  It may be associated
with various syndromes such as Noonan, Turner, Down`s syndrome, or primary
congenital pulmonary lymphangiectasis (King et al. 1991; Beghetti et al. 2000). The main
complications are pulmonary hypoplasia, fetal hydrops, and risk for premature delivery.
Several factors are important to the growth and maturation of the fetal lung, such as the
intrathoracic and intrauterine space available and the balance between pulmonary volume
and pressure (Laudy et al. 1996). Known risk factors for pulmonary hypoplasia are fetal
hydrops, renal anomalies, diaphragmatic hernia, omphalocele, skeletal anomalies, and
abnormalities of the amniotic fluid such as oligohydramnion and polyhydramnios. 
The etiology of isolated pleural effusion is in most case unknown. Possible causes
include congenital chylothorax, goiter, lung tumors, and infection. Cardiac defects and
Downs syndrome may be associated with fetal pleural effusion. Perinatal mortality is
high (36%) and related to the development of nonimmune hydrops, prematurity, and
pulmonary hypoplasia. Early gestation age (32 weeks or less) at diagnosis and fetal
hydrops is associated with poor prognosis and neonatal death (55%) (Longaker et al.
1989; Hagay et al. 1993).
Congenital cystic adenomatoid malformation is the most common type of fetal thoracic
mass diagnosed by prenatal ultrasonography (Dommergues et al. 1997). It is
characterized by an overgrowth of terminal respiratory bronchioles that form cysts of
various sizes. Congenital cystic adenomatoid malformation usually arises from one lobe
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of the lung, and bilateral lung involvement is rare. Prognosis depends on the size of the
malformation, polyhydramnios, and fetal hydrops. Hydropic fetuses may die in utero
because of mediastinal compression or during the neonatal period because of hypoplastic
lungs (Adzick et al. 1998; Adzick 2003).  Approximately 15% of congenital cystic
adenomatoid malformation lesions decrease in size during gestation, so the prognosis of
fetuses without hydrops and mediastinal compression is good (van Leeuwen et al. 1999).
Idiopathic arterial calcification of infancy is a rare condition inherited in an autosomal
recessive pattern (Hajdu et al. 1998).  If present in utero, the pregnancy is usually
complicated by polyhydramnios, fetal hydrops, and fetal demise (Carles et al. 1992).  It is
characterized by generalized medial calcification and intimae proliferation of major
arteries, leading to decreased vessel compliance and hypertension. Poor myocardial
function secondary to the myocardial infarction may result in heart failure (Green and
Laughlin 1996).
2.9.  PATHOLOGICAL SITUATIONS IN THE TRANSITION PERIOD
Severe perinatal stress can have profound effects on the myocardium of newborn infants
and result in myocardial dysfunction. Serious perinatal asphyxia with acidosis leads to the
most dramatic clinical and echocardiographic abnormalities. Degree of reduction in
cardiac output and stroke volume is proportional to severity of the clinical presentations
and can be explained by reduced LV contractility (Walther et al. 1985a). 
During the circulatory transition period, the various loading changes may produce
significant hemodynamic stress on the cardiovascular system of infants of very low birth
weight (VLBW). Preterm infants have less reserve capacity to increase stroke volume
when faced with left-to-right ductus arteriosus shunting than do mature infants. 
Preterm infants have lower LV contractility during the first few hours of life and are
therefore at risk for a diminished cardiac function if any complications such as perinatal
asphyxia or shock occur (Takahashi et al. 1997). In the premature heart, any increase in
cardiac output is due almost completely to changes in stroke volume; the increase in heart
rate may even diminish output (Winberg and Ergander 1992).
In sick preterm infants with worsening respiratory disease, low ventricular output is
common, and two negative influences seem to be mean airway pressure and ductal
shunting (Evans and Kluckow 1996). When cardiac function is quantified in ventilated
VLBW infants with acidosis and hypotension and compared to that of healthy preterm
infants, the median shortening fraction, LV contractility, and output are significantly
lower that in the control subjects. Cardiac dysfunction seems to be an important feature in
VLBW infants in cardiovascular collapse (Gill and Weindling 1993).
In a trial with serial pulsed Doppler assessment of early left ventricular output in
critically ill VLBW infants, Murase et al. found that initial LVO values at 3 hours of age
were relatively high. However, LVO dropped transiently at 12 hours and then increased
again after 24 hours, reaching a steady level of 160 to180 ml/kg per min after 48 hours of
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age. Both the left ventricular stroke volume and ejection fraction showed longitudinal
changes similar to the LVO. LVO values in the lower gestational age group were
significantly lower (Murase et al. 2002).
The most common inotropic agents for hypotensive preterm infants are dopamine and
dobutamine. At doses ranging from 2 to 10 µg/kg per min, dopamine raises blood
pressure through vasoconstriction, whereas dobutamine primarily raises blood pressure
by raising cardiac output, with only mild chronotropic and peripheral vascular effects.
Dopamine raises stroke volume and cardiac output because of its positive inotropic effect
on the myocardium. Infants treated with dopamine or dobutamine or both have a higher
cardiac output and heart rate than do normotensive controls. Supranormal cardiac output
(400 ml/min per kg) has been detectable in infants treated with both dopamine and
dobutamine. These may even be beneficial, as they maintain oxygen transport and
prevent redistribution of blood flow away from vital organs. Sustained myocardial
hypercontractility may, however, also be detrimental (Walther et al. 1985b).
Hemodynamic effects of blood transfusions in VLBW infants have been studied by
measurement of changes in cardiac output and blood pressure, with contradictory results.
Yu et al. (1998) studying acute effects of transfusion, found a significant drop in cardiac
index. A blood transfusion reduces cardiac output through a decrease in heart rate and
stroke volume (Nelle et al. 1994). In contrast, Pladys et al. (1997), found in preterm
infants that a 10% albumin solution (20 ml/kg) raised cardiac output significantly.
Anemia of prematurity raises heart rate, cardiac output, and stroke volume, and these
compensatory responses are normalized by transfusion (Hudson et al. 1990a; Bard et al.
1998).  With an increase in oxygen delivery after blood transfusion, the cardiac output
falls, due to an improvement in the oxygenation status of the patient (Möller et al. 1996).
NATRIURETIC PEPTIDES AND INTRAUTERINE GROWTH-RESTRICTION
Atrial and brain natriuretic peptides (ANP and BNP) are hormones produced by the heart
and released into the circulation in response to stretch (Levin et al. 1998). In postnatal
life, ANP is spread from granules in atrial myocytes in response to atrial distension and
hypervolemia. BNP is predominantly of ventricular origin, and its production is enhanced
in the presence of chronic congestive heart failure or LV hypertrophy (Yamamoto et al.
1996). The ANP gene is expressed in the fetal and neonatal ventricle. In utero, ANP has
been detected in blood from late-second-trimester human fetuses (Ville et al. 1994), and
concentrations do not change with gestation.  In healthy neonates, plasma BNP and ANP
concentrations are highest at one day of age and are significantly higher than on the day
of delivery. After the first full day of life, their concentrations steadily decrease (Mir et
al. 2003).
The elevated levels of ANP and BNP in the fetal circulation are associated with cardiac
overload, ANP with long-term overload and BNP with short-term volume load (Walther
et al. 2001). In the study by Bajoria et al., levels of ANP and BNP were elevated in utero
in recipient fetuses of twin-twin transfusion syndrome.  BNP levels were significantly
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higher in those recipient fetuses with severe cardiac dysfunction than in those with
normal function (Bajoria et al. 2002).
ANP and BNP enhance diuresis and natriuresis and reduce plasma volume, leading to
hemoconcentration and hypotension (Ville et al. 1994). Circulating levels of ANP and
BNP increase in patients both with left ventricular hypertrophy and with dysfunction
(Lerman et al. 1993). Plasma BNP concentration correlates with the LV mass index in
patients with hypertension (Kohno et al. 1992). As in adults, plasma concentrations of
ANP are elevated in infants with left atrial distension (Pesonen et al. 1990), and they
decrease after left atrial size normalization (Andersson et al. 1987).
In growth-restricted fetuses, plasma ANP and BNP concentrations are increased. This has
been reported in studies of cord blood at delivery both in intrauterine growth retardation
and in preeclampsia. These findings are compatible with impairment of cellular
metabolism; both increased vascular resistance in the placenta and hypoxic heart failure
can lead to atrial distension or myocardial infarction or both; or to increased ANP and
BNP secretion (Kingdom et al. 1992). Concentrations of ANP are highest in fetuses with
myocardial cell damage (Mäkikallio et al. 2002b). It is possible that increase in ANP and
BNP may represent an adaptive response by the fetuses under stress to maximize
fetoplacental blood flow and oxygen transport (Ville et al. 1994).
The finding that levels of ANP and BNP are significantly higher in infants with antenatal
magnesium administration than in those without suggests that the natriuretic peptide
system plays an important role both in intrauterine and in postnatal cardiac function,
filling pressures, and hypertrophy (Okumura et al. 2002). Maternal hypertensive disorder
and fetal acidemia during labor stimulate fetal atrial natriuretic peptide production
(Mäkikallio et al. 2001).
36
3.   AIMS OF THE PRESENT STUDY
The hypothesis of this series of studies was that echocardiography is a reliable method to
diagnose cardiovascular pathology in fetuses and neonates.
Therefore, the purpose of this work was, by means of echocardiography, to evaluate the
etiology and outcome of fetuses and infants with cardiovascular disease. 
The specific aims were to study:
1. the outcome of fetuses with antenatal diagnosis of congenital structural heart
disease (I)
2. the outcome of fetuses with functional heart disease  (II)
3. the outcome of fetuses with cardiac arrhythmias, and retrospectively the effects of
the intrauterine therapy (III)
4. and to estimate the hemodynamic adaptation in very low birth weight infants after
intrauterine growth retardation (IV).
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4. MATERIALS AND METHODS
4.1. STUDIES I-III
4.1.1. Patients and Study Designs
All fetal studies were retrospective. Between January 1983 and December 2001, of the
872 pregnancies referred to a pediatric cardiologist for detailed echocardiography at the
Hospital for Children and Adolescents, 442 cases with prenatal diagnoses of intrauterine
cardiovascular disease were detected.
Indications for prenatal ultrasound examination were abnormal four-chamber views, a
strong family history of congenital heart disease, fetal heart arrhythmia, extracardiac
malformation, fetal hydrops, maternal diabetes, polyhydramnios, multiple gestation,
chromosomal abnormality, or cardiac teratogen.
Inclusion criteria were an intrauterine cardiovascular disease confirmed postnatally or at
post-mortem examination (Studies I and II) or documented intrauterine arrhythmia and a
complete follow-up in utero and after birth (Study III). 
As obstetric data, the presence of any extracardiac anomalies or chromosomal
abnormalities was recorded, and transplacental treatment documented. Pregnancy
outcome was defined as termination of pregnancy, spontaneous intrauterine death, or
perinatal and neonatal mortality. Fetal heart failure was defined as pericardial effusion
(fluid in pericardium in diastole) or hydrops (presence of fluid in at least 2 cavities).
Immediate neonatal course was evaluated in terms of gestational age at delivery, birth
weight, Apgar scores at 1 and 5 min, umbilical artery pH, and base excess. In the
neonatal period the diagnosis was confirmed by echocardiography. Need for respiratory
treatment and vasoactive, prostaglandin, or antiarrhythmic therapy was recorded, and also
age at any intervention (heart catheterization, pacemaker application, or heart surgery).
The clinical status of every individual patient was analyzed in the follow-up. 
The study population was divided into three subgroups depending on etiology of the heart
disease. These subgroups were: 
I Fetuses with structural heart disease (99 cases);
II    Fetuses with functional heart disease (51 cases);
III   Fetuses with cardiac arrhythmias (292 cases).
Inclusion criterion for subgroup I was a structural heart disease detected by
echocardiography in utero and confirmed postnatally, and for subgroup II a functional
heart disease (fetal hydrops, pericardial effusion, tricuspid valve regurgitation,
hypertrophic cardiomyopathy, or dilated cardiomyopathy) without structural heart disease
or arrhythmia.
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Hydrops was diagnosed when there was a presence of fluid in at least two cavities.
Pericardial effusion was diagnosed at 5 mm or more fluid in the pericardium at the
atrioventricular valve junction during diastole. Tricuspidal valve regurgitation was
diagnosed as a holosystolic regurgitant flow in the four-chamber view, hypertrophic
cardiomyopathy if septum diameter was more than +2 SD. Dilated cardiomyopathy was
diagnosed in cases of univentricular or biventricular systolic dysfunction with or without
significant chamber enlargement, but without increased wall thickness.
For subgroup III, the inclusion criterion was a cardiac arrhythmia detected and followed
in utero (Table 2). 
Table 2.  Populations in Studies I-III.
Cardiac disease Study I:
Structural
heart disease
Study II:
Functional
heart disease
Study III:
Fetal arrhythmia
Number of patients 93 51 292
Gestational age at
diagnosis, in weeks
Median (range)
28
(16-41)
28
(20-40)
31
(15-41)
Gestational age at birth,
in weeks
Median (range)
38
(27-42)
34
(25-41)
38
(23-42)
Birth weight in grams
Median (range)
2878
(940-4888)
2512
(550-4830)
3330
(790-5000)
Gender, male / female n 57/36 25/24 164/128
Delivery mode
Cesarean section/vaginal
26/50 37/12 88/204
In-utero medication,
n (%)
4
(4%)
9
(18%)
48
(16%)
Cardiac anomalies, 
n (%)
93
(100%)
0 34
(12%)
Chromosomal
anomalies, n (%)
26
(28%)
1
(2%)
5
(1.7%)
Fetal death, n (%)
Abortion, n (%)
 7 (8%)
10 (11%)
2 (4%)
2  (4%)
7 (2%)
0
Postnatal death / alive, n 42 / 34 12 / 35 21 /264
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4.1.2. Fetal Echocardiography
In Studies I to III, the fetal heart was examined with M-mode, two-dimensional-guided,
pulsed, continuous wave, and color Doppler equipment (Advanced Technology
Laboratories 600 MK, Toshiba SSH 65 A and Acuson 128 Color Doppler systems) with
3.5 and 5 MHz transducers. Two-dimensional imaging was obtained from five
approaches including four-chamber (Figures 1. and 3.), five-chamber (Figure 2.), long
axis, short axis, and arch views with recording of heart rate and presence of fetal
arrhythmias, hydrops, pericardial effusion, or valve regurgitations. All studies were
performed by the standard transabdominal approach. The studies in which abnormalities
appeared were recorded on videotape for subsequent playback and analysis. 
Figure 1.  An apical four-chamber Figure 2.  A five-chamber view   
view. demonstrating aorta. 
Figure 3.  An apical view of univentricular heart.
In Study III, fetal arrhythmias were divided into atrial extrasystoles, atrial tachycardias
(Figure 4.), atrioventricular block (Figure 5.), sinus bradycardia, and ventricular
extrasystoles. The atrial tachycardias were classified as supraventricular tachycardia if
there was a 1:1 atrioventricular connection, and as atrial flutter (AF) if the atrial rate
exceeded the ventricular rate. Sinusbradycardia (SB) was defined as an atrial guided
ventricular rhythm of less than 110 beats per minute. This study included no fetuses with
ventricular tachycardia.
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Figure 4. Atrial flutter – M-mode. 
Atrial flutter with 2:1 A:V block
Figure 5. Atrioventricular block – M-mode.
The atrial contraction 170 beats/min, ventricular contraction 51 beats/min.
The median gestational ages at diagnosis are presented in Table 2. The patients were
followed in the Hospital for Children and Adolescents by a pediatric cardiologist at
intervals of 1 to 4 weeks, depending on fetal diagnoses. If a medication was started, the
next checkup was a few days after initiation of drug therapy. The last fetal examination
was always planned to take place close to estimated delivery. 
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4.1.3. Neonatal Echocardiography
All infants born alive were studied by a pediatric cardiologist on the first day of life.
Neonatal studies included two-dimensional, M-mode, and Doppler measurement in the
standard projections:  subcostal view, four-chamber view, five-chamber view, long- and
short-axial parasternal views, and suprasternal view, with examination of the anatomy of
the atriums, atrioventricular valves, ventricles, and septums. The semilunar valves,
outflow tracks, and the great vessels were evaluated and flow in the ductus arteriosus
examined. All studies were recorded on videotape. 
M-mode measurements were for evaluation of left and right ventricular dimensions,
thickness and motion of the ventricular walls, left ventricular ejection fraction, and
fractional shortening. M-mode recordings of the LV came from the parasternal long axis
view at the junction of the mitral valve leaflet tips and the papillary muscles or chordae
tendinae.
4.1.4. Postnatal Follow-up
During follow-up, the clinical status of every individual patient was evaluated, and
postnatal events such as surgery, arrhythmias, cardiac insufficiency, medication,
neurological mortality, and death registered. No patients lacked follow-up data.
In each fetal or neonatal death, an autopsy was performed. 
Follow-up times for these three studies were:
1. Study I: median 3.8 years,
2. Study II: median 3.9 years,
3. Study III: median 5.0 years. 
4.2. STUDY IV
The neonatal study population comprised 63 consecutive newborn infants born in the
maternal unit of Helsinki University Hospital and treated in the neonatal intensive care
unit of the same hospital between 1998 and 2000. This study was prospective and both
cross-sectional and longitudinal. There were altogether 96 echocardiographic evaluations,
of 33 newborns once, of 27 twice, and of 3 three times. 
Infants of birth weight less than 1500 g and with in-dwelling arterial lines were enrolled
if the birth weight was less than 2 SD (SGA) or within ± 1 SD range (AGA). Infants
with acute birth asphyxia (umbilical artery pH less than 7.1), chromosomal abnormalities,
or major congenital heart disease were excluded. Gestational ages were determined by
fetal ultrasonography (Table 3).
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Table 3. Characteristics of the Study  IV population
(Values are mean ± SD, ٭p vs AGA < 0.01)
AGA (n=32) SGA (n=31)
Gestational age at birth
(weeks)
27.2 ± 1.8
(24.0-30.9)
28.4 ± 2.4
(23.3-32.4)
Birth weight (g) 1006 ± 215
(630-1485)
810 ± 242
(405-1300) ٭
Male / Female, n 21 / 11 22 / 9
Antenatal steroid, n (%) 28 (88%) 28 (90%)
Pre-eclampsia, n (%) 4 (13%) 19 (61%)
4.2.1. Monitoring
Systolic, diastolic and mean arterial blood pressure, heart rate, and oxygen saturation
were continuously monitored, and notropic medications, blood transfusions, and other
intravenous fluids recorded, as was capillary refill time. All monitored values were
recorded immediately before the echocardiography. 
4.2.2. Echocardiographic Studies
All the echocardiographic studies were made with an Acuson 128/XP10 scanner (7 MHz)
and videotaped, and the anatomy of the heart examined. The presence of ductus arteriosus
was defined. M-mode measurements were made from the parasternal long axis view.
End-diastolic diameters of the left ventricle (LVEDD), diastolic interventricular thickness
(IVSD), left ventricular shortening fraction (LVSF), and ejection fraction (LVEF) were
recorded as described above. To obtain the left ventricular cardiac output and stroke
volume, the internal diameter of the aortic annulus and the flow velocity integral of the
maximal velocity of the ascending aorta were measured. Left ventricular output was
calculated with the equation: LVO = cross-sectional aortic area (cm²) multiplied by flow
velocity integral (cm) multiplied by heart rate per minute. 
Intraobserver variability was calculated between the analyses from the observer`s two
examinations. In this study, ten patients were enrolled for this purpose. Intra-observer
variability was calculated as the standard deviation of the differences between two
measurements and expressed as percentage of the averaged value.
Echocardiographic studies were made on days 1, 2, or 3 (analyzed separately), and on
days 4 to 6 (mean 5) and 7 to 14 (mean 10).
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4.2.3. Biochemical Measurement
Brain natriuretic peptide (BNP) concentrations were measured by RIA after extraction of
the samples with SepPak C18 cartridges. Assay sensitivity was 0.3 fmol/tube. The within-
and between-assay coefficients of variation were <10 and <15%, respectively. The assay
does not cross-react with atrial or C-type natriuretic peptide (<0.1%). With this method,
BNP level in the plasma of healthy adults was 3.8 ± 3.4 pmol/L. In healthy neonates,
plasma BNP concentration is highest at the age of 0 (up to 30 times as high as the adult
level) and decreases thereafter, reaching the adult level at 3 months of age (Yoshibayashi
et al. 1995). The blood sample was drawn immediately after echocardiography, before
transfusion.
Blood volume assessment was performed by a modification of the Hb subtype method
described by Phillips et al. (1986). An arterial blood sample was drawn before
transfusion, and then 15 min after the transfusion. Hb subtypes HbF and HbA were
separated by liquid chromatography by PolyCAT A-cation exchange column (PolyLC
Inc.) and determined by an Applied Biosystems absorbance detector. RVC and BV were
calculated, based on change in the relative amounts of Hb subtypes caused by the
transfusion. 
5. STATISTICS
Patient characteristics are expressed as mean ± SD or as median and range, and results
are expressed as mean and standard deviation (mean, SD). 
Statistical differences between the clinical variables of the study groups were examined
through the unpaired t-test, Mann-Whitney U-test, and X² analysis (I, II, III). The t-test
was used for continuous variables and the Mann-Whitney U-test for non-parametric data
to compare the two subgroups. In addition, a series of multiple regression analyses and
logistic regression analysis was used to learn which variables best predicted neonatal
outcome (death or life).
In Study IV, data were analyzed by one-way ANOVA, two-tailed Students t test, X² test,
and Wilcoxon rank sum test.
A p value < 0.05 was considered significant.
6. ETHICS
The hospital ethics committee approved these studies with written informed parental
consent obtained before enrollment (Study IV).
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7. RESULTS
7.1. STRUCTURAL HEART DISEASE (I)
The study population (Study I) comprised 99 fetuses with prenatal diagnoses of
congenital structural heart disease, of which, six showed normal cardiac anatomy
postnatally and were excluded from further analyses. Of the diagnoses, 54 were made
between the years 1995 to 1999 and 45 before the year 1995. 
Median maternal age at delivery was 29.4 years (range 16-46). Median gestational age at
diagnosis was 28.4 weeks (range 16-41); in 28 (30%) cases, the diagnoses were made
before 24 weeks of gestation. Of the fetuses with a cardiac defect diagnosed before 24
weeks of gestation, 35% were aborted.
CHROMOSOMAL AND EXTRACARDIAC ANOMALIES
Table 4 shows the cardiac, extracardiac, and chromosomal anomalies diagnosed. A
chromosomal abnormality occurred in 26 (28%) of these fetuses. Of the fetuses with 18-
trisomy, 3 died in utero and 10 after birth. Mortality among the 26 fetuses with a
chromosomal abnormality was very high, 19 (73%); all survivors had 21-trisomy. 
Of the 67 fetuses with a normal karyotype, 27 (40%) had extracardiac anomalies.
Anomalies of the gastrointestinal system were the most usual; others were in the
respiratory tract, urogenital system, labiopalatoschisis, central nervous system, skeletal
system, and extremities, with many of the fetuses showing multiple anomalies. The
highest frequency of extracardiac anomalies with a normal karyotype appeared in fetuses
with AVSD  (with atrial isomerism), 80%. Presence of extracardiac anomalies was more
frequently associated with postnatal death (p=0.03). 
INTRAUTERINE HEART FAILURE
Of the 93 fetuses, intrauterine heart failure was detected in 25 (27%), being most frequent
in those with univentricular heart (UVH, 36%) or intracardiac tumors (67%). Cardiac
failure seemed to associate with poor outcome; although the difference was not
statistically significant (p=0.08).  Twelve fetuses (13%) had associated arrhythmias
(UVH and AVSD with sinusbradycardia, UVH with AV-block, TOF+APV with
ventricular ectopics); in four cases (33%), this led to death.  
FETAL DEATH
Of the 93 mothers, ten opted for pregnancy termination at a median gestational age of 21
weeks (range 18-24), but only 30% of mothers had been referred to a pediatric
cardiologist before 24 weeks of gestation and thus only these had even had the option of
termination; 35% of these chose termination. Among these fetuses, three had extracardiac
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anomalies with complicated heart defect (1 UVH, 1 HLHS, 1 TOF + absent pulmonary
valve). Among the terminated pregnancies, the fetuses had no chromosomal anomalies.
Of the 93 fetuses, 7 (8%) died in utero at a median 33 gestational weeks (range 27-37
weeks). Of these, 4 had chromosomal abnormalities and 3 had heart defects with multiple
extracardiac anomalies.
LIVE BIRTHS
There were altogether 76 live births, with a median gestational age of 38 weeks (range
27-42) and a median birth weight of 2878 g (range 940-4888). Of these 76 cases, delivery
by cesarean section was performed in 26 (34%), in 6 cases due to intrauterine heart
failure (1 hydrops, 5 pericardial effucions); 50 (66%) neonates needed intensive care
(Table 5), 8 (10%) requiring invasive procedures in the early neonatal period. Six
neonates subsequently underwent cardiac surgery in the first week of life (Table 6). Of
the 15 babies with HLHS, 8 were born after 1995 and had as an option the Norwood
operation; but only 3 of them underwent the first stage of the Norwood surgery. 
In total, 24 infants (32%) underwent the first step of cardiac surgery or any invasive
procedure before the age of 1 month; 6 infants (25%) died after this procedure. Among
the infants operated on after 1 month of age, only one postoperative death occurred. A
total of five infants died during follow-up (Table 5). 
Overall mortality was very high, 63%, and neonatal mortality 49%. At long-term follow-
up of a median 3.8 years, of 76 neonates, 34 (45%) with heart defects were alive (Table
5).
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Table 4.  Cardiac (N=93), chromosomal (N=26) and extaracardiac (N=27) anomalies in 
Study I.
Cardiac anomaly N Chromosomal
anomaly N
Extracardiac
anomaly N
HLHS                  20 2 (18-trisomy) 4
VSD                    16 5 (18-trisomy
2 (21-trisomy)
2 (others)
3
 UVH                  14 3 (18-trisomy) 3
AVSD                 12 1 (18-trisomy)
6 (21-trisomy)
4
TOF                      7 1 (18-trisomy)
1 (other)
3
DORV                  6 1 (18-trisomy) 3
Tumors                 3 0 2
PAIVS                  2 0 0
RV-hypoplasia     2 0 1
Truncus arteriosus 2 1 (9-trisomy) 0
ASD sec                2 1 (21-trisomy) 1
Ectopia cordis       1 0                                            1
cTGA                   1  0 0
AS                         1 0 0
Thoracopachus      1 0 1
Ebstein´s anomaly 1 0 0
PS         1 0 0
CoA                      1 0 1
TOTAL               93 26 27
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Table 5.  Postnatal treatment and interventions of neonates with cardiac anomalies
diagnosed in utero in Study I.
Cardiac
anomaly
n Neonatal
Intensive
Care
Neonatal
cardiac
intervention
Heart
surgery
<1
month
Heart
surgery
>1
month
Alive Age at
follow-up
months
(range)
HLHS < 95
           > 95                
7
8
0
7
0
0
0
3
0
0
0
2
0
19 (2-36)
VSD 14 5 0 2 2 5 30
(18-48)
UVH  8 7 3 3 0 4 54
(18-72)
AVSD 11 7 0 3 5 6 52
(3-156)
TOFAPV  6 4 0 2 2 4 61
(1-144)
DORV  5 5 1 1 3 4 17
(6-48)
TUMORS  3 3 0 0 0 2 30
(24-36)
PAIVS  2 2 2 2 0 1 1
RV-hypoplasia  2 2 0 1 0 1 2
Truncus  1 1 0 1 0 0 0
ASD sec  2 1 0 0 0 2 48
(46-50)
Ectopia cordis  1 1 0 1 0 0 0
cTGA  1 1 1 0 0 1 30
AS  1 1 1 0 0 0 0
Thoracopachus  1 1 0 0 0 0 0
Ebstein`s
anomaly
 1 1 0 0 0 0 0
PS  1 0 0 1 0 1 72
CoA  1 1 0 0 0 1 3
TOTAL 76 50 8 20 12 34
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7.2. FUNCTIONAL HEART DISEASE (II)
The study population (Study II) ccomprised 51 fetuses of 41 mothers referred for detailed
fetal echocardiography performed by a pediatric cardiologist from January 1990 to July
2000. Inclusion criteria were hydrops (n=14), pericardial effusion (n=9), tricuspidal valve
regurgitation (n=8), hypertrophic cardiomyopathy (n=7), and dilated cardiomyopathy
(n=7). Six fetuses in twin pregnancies had normal cardiac function.
Maternal age was a median 29.8 years (range 21-41), and diagnoses of functional heart
disease were made at a median 28.6 weeks of gestation (range 20-40). Gestational age at
delivery was a median 34.0 weeks (range 25-41). For these 25 males and 24 females,
median birth weight was 2512 g (range 550-4830). Delivery route was vaginal in 12,
cesarean section in 21, and emergency cesarean section in 6; two fetuses were aborted. 
ETIOLOGY, SYMPTOMS, AND OUTCOME
Of the 49 fetuses, 15 (31%) had antenatal management: 9 digoxin administration for high
output or anemia, 3 thoracocentesis, 1 pericardial puncture, 1 blood transfusion, and 1
ascites centesis. Of 9 fetuses with maternal digitalization, 6 (66%) died. However, no
mortality occurred after thoracocentesis, pericardial centhesis, or in-utero blood
transfusion. Of fetuses receiving antenatal treatment, 53% survived. 
In the whole study population (N=51), fetal mortality was 29%, that of fetuses with
functional heart disease was 33%, excluding terminated cases. Fetal hydrops was
associated with very poor prognosis; 9 of 14 (64%) died: in 4, the etiology of hydrops
was anemia, in 3, inadequate perfusion, and in 2, malformations. Moreover, pericardial
effusion, dilated cardiomyopathy, and tricuspidal valve regurgitations were associated
with respective mortalities of 25%, 25%, and 17% (teratoma, indomethacin exposure).
No mortality was associated with hypertrophic cardiomyopathy; 30% of the fetuses with
high output cardiac failure had hydrops (Table 6).
In long-term follow-up, 35 patients are at present alive, and of these, 30 are free of
symptoms. Among the 5 symptomatic patients are 1 with cardiomyopathy, 2 siblings with
hemolytic anemia, and 2 with neurological handicap.
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Table 6.  Etiology, symptoms, and outcome of fetuses with functional heart disease
(Study II)
SYMPTOMS OUTCOME
Etiology n hydrops DCM HCM pericardial
effusion
tricuspidal
regurgitation
normal Death in
utero/
terminatio
postnatal
death/alive
Abnormal
peripheral
impedances
3 1 0 0 0 2 0 0 2/1
High output /
anemia
26 8 1 3 5 3 6 1 6/19
Myocardial
dysfunction
10 1 2 4 2 1 0 0 2/8
Noncardiac
malformations
9 3 3 0 2 1 0 2 2/5
Others 3 1 1 0 0 1 0 1 0/2
Total 51 14 7 7 9 8 6 4 12/35
7.3. CARDIAC ARRHYTHMIAS (III)
This retrospective, follow-up study included 292 consecutive fetuses diagnosed between
1983 and 2001 with cardiac arrhythmia. Indications for referral to a pediatric cardiologist
were arrhythmia (n=269), abnormal four-chamber view (n=12), strong family history of
congenital heart disease (n=4), small for gestational age (n=3), fetal hydrops (n=2),
extracardiac malformation (n=1), and maternal diabetes (n=1). Chromosomal anomalies
appeared in 5 (1.7%) fetuses. In-utero cardiac failure was demonstrated in 11% and
intrauterine medication administered to 16%. There were 7 intrauterine deaths (2%). In
total, 34 (12%) had cardiac anomalies, 3 (1%) cardiac tumors, 6 (2%) cardiomyopathy,
and 2 (1%) endocardial fibroelastosis.
ATRIAL EXTRASYSTOLES
Incidence of atrial extrasystoles among the 292 was 200 (68%). Seven fetuses (3.5%) had
bigeminy and multiple extrasystoles and received in-utero medication (digoxin), and 21
had extrasystoles that led to intermittent bradycardia of 70 to 90 beats/min. In-utero
cardiac failure was detectable in 3 (1.5%); all of these had cardiac anomalies. Altogether,
17 (9%) were diagnosed with structural heart defects. 
ATRIAL TACHYCARDIA
Of the whole study population, 35 (12%) fetuses had atrial tachycardia. Median
gestational age at presentation was 31.6 weeks (range 19 to 41). Of 35 fetuses,
supraventricular tachycardia was present in 21 (60%), atrial flutter in 13 (37%); 1 fetus
had intermittent supraventricular tachycardia (3%). Based on clinical manifestation, the
fetuses were divided into nonhydropic (n=27) and hydropic (n=8) (Figure 6.).
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amiodarone
 n=1
sotalol n=3 propranolol n=3
sotalol
 n=1
flecainide  n=3 amiodarone n=3
digoxin
 n=26
no fetal hydrops
 n= 26
propranolol n=1
propranolol n=2
flecainide n=1
amiodarone n=3 flecainide n =1
digoxin n=6 amiodarone n=1
fetal hydrops
 n= 8
 ATRIAL TACHYCARDIA DRUG THERAPY
 N=34
Figure 6.  Flow chart illustrating drug therapy for no fetal hydrops and fetal hydrops,
according to clinical manifestation.
Among the 27 fetuses without hydrops, 17 had supraventricular tachycardia, 9 atrial
flutter, and 1 intermittent atrial tachycardia. For the 26 treated, maternal digoxin was
started as the first drug. Of these, 14 (54%) converted to sinus rhythm. In the remaining
12 fetuses, digoxin was combined with a second drug (Figure 1).
Of the total of 25, 23 (92%) surviving fetuses were converted to sinus rhythm in utero.
Digoxin alone was effective in 54%. Of the 12 fetuses with a second drug administered,
sinus rhythm was achieved in 9 (75%). A third drug was needed for 2 of 26 (8%), but in
these two cases, no conversion to achieved to sinus rhythm. Direct fetal amiodarone
therapy was given to 3 nonhydropic fetuses. Two converted to sinus rhythm, and one
developed bradycardia and asystole and died in utero at 27 gestational weeks.
In-utero sinus rhythm was achieved in 5 of 8 (63%) fetuses with hydrops. Neither digoxin
nor propranolol had any preventive effect against atrial tachycardia. Amiodarone
converted atrial tachycardia to sinus rhythm in all, but caused severe bradycardia in one
fetus. Flecainide was effective in one. Altogether, hydrops led to much higher mortality
than nonhydrops (38% vs. 3.7%, p< 0.01). Median gestational age at birth was
significantly lower in hydropic than nonhydropic fetuses (mean 33.6 ± 3.5 weeks vs.
mean 38 ± 2.9 weeks; p< 0.01).
ATRIOVENTRICULAR BLOCK
Atrioventricular block was diagnosed in 36 fetuses, comprising 12% of the whole study
population. Isolated atrioventricular block was present in 30 of these with, 6 fetuses
having structural heart disease with atrioventricular block. Of mothers whose fetuses had
isolated atrioventricular block, 96% showed connective tissue disease confirmed by
positive anti-Ro/SS-A antibodies. Fetuses with structural heart disease had a poor
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outcome: one died in utero and another at the age of 1 day (both had left atrial
isomerism). 
In this group, median fetal heart rate was 59 beats/minute (range 30-100 beats/min). 
Cardiac failure (4 hydrops and 6 pericardial effusions) occurred in 10 fetuses.
Autoimmune myocarditis developed in 5 (17%) with isolated atrioventricular block.
Altogether 9 fetuses received medication in utero (4 digoxin, 2 digoxin and salbutamol, 2
salbutamol, 1 dexametason); 3 fetuses on medication died postnatally.
Antenatal findings associated with poor outcome were in-utero cardiomyopathy and
autoimmune myocarditis with pericardial effusion or hydrops or both (2 fetal, 3 postnatal
and 1 late deaths). Of 10 fetuses with cardiac failure, in 8, heart rate was 55 beats per
minute or less.
SINUS BRADYCARDIA
Among 14 fetuses with sinus bradycardia, cardiac anomaly was evident in 6 (43%), who
suffered intrauterine (2) and postnatal death (3). Of these 14 fetuses, 3 had long QT-
syndrome diagnosed postnatally, in only 2 was sinus bradycardia an innocent finding. 
VENTRICULAR EXTRASYSTOLES
In this series of 292, ventricular extrasystoles appeared in only 7 (2%) fetuses. Cardiac
defects or tumors were diagnosed in 5(71%), of whom 3 had trisomy 18 with a poor
prognosis.
POSTNATAL FOLLOW-UP AND OUTCOME
Table 7 presents the postnatal outcome in Study III.
Table 7.  Fetal arrhythmia, postnatal outcome Study III
 
Type of arrhythmia 
n
AES
200
AT
34
AVB
33
SB
12
VES
6
TOTAL
285
Follow-up time, years
Median (range)
4.3
(0-11)
4.9
(0-14)
6.8
(2-14)
9.9
(0-14)
4.8
(0-17)
5
(0-17)
Postnatal medication
n (%)
11
(5.5%)
21
(60%)
9
(27%)
8
(67%)
2
(33%)
51
(18%)
Pacemaker application
n (%)
0 0 29
(88%)
2
(17%)
0 31
(11%)
Alive at follow-up, 
n (%)
193
(97%)
31
(91%)
27
(82%)
9
(75%)
4
(67%)
264
(93%)
Neurological injury, 
n (%)
0 5
(16%)
1
(4%)
0 1
(25%)
7
(3%)
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ATRIAL EXTRASYSTOLES
In the median follow-up time of 4.3 years, of the 200 fetuses, 7 deaths were associated
with structural cardiac anomaly. None of these children had developed any neurological
disorder. Postnatal medication was administered to 11 (5.5%) of the 200, of whom, 7 had
structural heart defects and 1 cardiac tumor (multiple rhabdomyomas). Two infants
developed supraventricular tachycardia (1%) postnatally and one had atrial extrasystoles
with bigeminy. 
ATRIAL TACHYCARDIA
Nonhydropic fetuses
In the median follow-up time of 4.9 years (range 1-14), of the 26, antiarrhythmic therapy
was administered to 17 (65%) live-borns during a median treatment time of 10.5 months
(range 1 to 84 months). Three children developed a neurological disorder: 1 had tuberous
sclerosis, 1 arachnoidal cyst, and 1 a mild neurological handicap. 
Hydropic fetuses
In follow-up, of the 5 children surviving, 4 recieved postnatal drug therapy for a median
period of 8.8 months (range 2-18), and neurological morbidity was diagnosed in 2 (40%).
Risk for neurological morbidity was significantly higher in hydropic than nonhydropic
fetuses (40% vs. 12%, p=0.01).
ATRIOVENTRICULAR BLOCK
Postnatally, pacemaker implantation was performed in 24 (86%) of the 28 live-born
infants during the neonatal period. Three infants with isolated atrioventricular block
developed late-onset cardiomyopathy: 1 died at the age of 3 years, and two underwent
cardiac transplantation. The total survival rate was 82% in the median follow-up time of
6.8 years.
Children with structural heart disease had poor prognosis; of the 6, only 3 are at present
alive beyond the age of 3 years. 
SINUS BRADYCARDIA
In this group of children, only 9 patients lived past the neonatal period, one with
structural heart disease; 3 children with long-QT syndrome are now on cardiovascular
medication with beta-blockers.
VENTRICULAR EXTRASYSTOLES
Of the 6 infants, among the 4 surviving, two were without any heart defect. One of them
had ventricular tachycardia postnatally and was treated with beta-blockers.
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7.4. CARDIAC HYPERTROPHY AND ALTERED HEMODYNAMIC
ADAPTATION IN GROWTH-RESTRICTED PRETERM INFANTS (IV)
Characteristics of the study population are shown in Table 2. Preeclampsia was the most
common cause of growth retardation. No cases of maternal malnutrition appeared in the
study population. 
After growth restriction, cardiac diameters in relation to weight were increased. Serum
BNP correlated significantly with both IVSD (r= 0.727, p< 0.01) and LVEDD (r= 0.317,
p< 0.05). Serum BNP was 28 ± 13 pmol/L in the AGA and 48 ± 53 pmol/L in SGA
infants (p< 0.05).
Initially, LVO was larger in the SGA than in the AGA infants (243 ± 47 vs. 150 ± 28
mL/kg/min, p< 0.05). A gradual increase in LVO occurred during the study period in the
AGA infants (LVO was increased by 39% on day 3 and by 89% at the end of the study),
whereas in the SGA infants no LVO increase occurred. This difference was also observed
in the infants studied repeatedly: in the 12 AGA infants studied twice, LVO was 200 ± 54
mL/kg/min in the first and 247 ± 68 mL/kg/min in the second assessment (p< 0.05),
whereas in the SGA infants studied twice (n =15), the LVO remained similar (224 ± 105
vs. 246 ± 57 mL/kg/min, NS). 
There occurred a close correlation of LVO with SV (r= 0.927, p< 0.01), but no significant
correlation with mean arterial blood pressure. Similarly to LVO, SV on day 1 was
significantly greater in the SGA than in the AGA infants (1.51 ± 0.32 vs. 0.95  ± 0.17, p<
0.05), and did not increase in the SGA infants thereafter. The indices of contractility did
not differ between groups: mean LVFS of all measurements was 36 ± 6.2% in the AGA
and 36.7 ± 6.2% in the SGA infants, mean LVEF 70.4 ± 7.9% and 70.8 ± 8.6%,
respectively. At the time of the study, mean heart rate was 158 ± 15.8 beats per minute in
the AGA infants, and 158 ± 16.4 in the SGA infants. No significant differences were
evident when data from the different study times were analyzed separately, and no
difference between the 13 AGA infants and 18 SGA infants treated with catecholamines. 
RCV and BV did not differ between the groups initially, but both volumes increased in
the AGA infants during the first 3 days of life, and were significantly higher on day 3
than on day 1. Compared with day 1, RCV and BV remained unaltered until the end of
the first week in the SGA group. RCV correlated with hematocrit (r= 0.569, p< 0.01) but
not with LVO, systolic blood pressure, mean arterial blood pressure, heart rate, and
capillary refill time. BV correlated significantly only with RCV (r= 0.892, p< 0.01).
There were no significant differences in the indirect indices of hemodynamics between
the AGA and SGA infants. Of the 17 SGA infants examined on days 1 to 2, open ductus
arteriosus was detected in 8 (47%) and of the 15 AGA infants in 7 (47%). After day 3,
only 3 SGA infants and 5 AGA infants had open ductus arteriosus.
The intra-observer variability for this observer was calculated from the measurements of
the aortic diameters; the within-observer variability constituted 5.8% of the total
variability in a single measurement.
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8. DISCUSSION
8.1. Fetal Studies (I-III)
During the study period, a universal anatomical scan of the fetus was being performed in
most obstetric centers in Finland between 18 and 20 weeks of gestation. In our studies,
our first patients included originated from the early 1980s. During the study period, both
the ultrasound methods and the fetal and postnatal therapies have undergone changes. At
the beginning of the study period, cardiac screening usually included only the four-
chamber view. During the last few years, the great arteries have also been scanned to
screen for defects. One of the most promising methods in clinical practice is
measurement of nuchal translucency thickness, which is performed in early pregnancy
(10-14 weeks). This screening program has already had important implications for
improved detection of both chromosomal and cardiac malformations (Taipale et al. 1997;
Hiippala et al. 2001; Galindo et al. 2003). 
Limitations of these fetal studies 
Since all the fetal studies were retrospective, treatments given to the fetuses were
impossible to influence.  The methods of treatment of fetal arrhythmia have also varied
from case to case; there was no standardized treatment protocol.  
The time interval during which these cases have been collected has been so long that
methods of treatment have developed. From 1995 to 2001, cardiac surgery before the age
of one month has increased from 50 to 100 operations per year. In the early 1990s,
surgical mortality was 6 to 7%, decreasing to 3 to 4% in 2001.  In Finland, no newborns
with the diagnosis of left heart hypoplasia underwent surgery before the year 1995. In the
beginning, surgical mortality was about 60 to 70% in Norwood I-operations, but in the
2000s it has dropped to 10%. 
Of fetal diagnoses in Study I, 58 of 99 were made between 1995 and 1999.  The major
part of the diagnoses before 1995 were complex structural heart anomalies like
univentricular heart (10 fetuses) and hypoplastic left heart syndrome (10) or lethal
chromosomal anomalies (7). This may be one explanation for the poor outcome of the
fetuses with structural heart defects.
The fetal study population (Studies I-III) is a highly selected group of patients. In Study
III, the indication for referral to a pediatric cardiologist was not always arrhythmia, but
could also be an abnormal four-chamber view (12 fetuses) or risk for cardiac
malformation (11). This may be one explanation for the high percentage of structural
anomalies in fetuses with atrial extrasystoles compared to figures in other studies
(Simpson and Marx 1994; Allan 1996).
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Fetal screening for cardiac disease
Cardiac anomaly is the most common congenital abnormality, affecting 7 to 8 per 1000
of all live births. The fetal detection rate for congenital heart defects continues to
increase, and the accuracy of fetal echocardiography examinations now allows
arrangements for management of the neonate with congenital heart disease in advance of
delivery (Huhta 1995; Tometzki et al. 1999; Brick and Allan 2002). Detection of fetal
heart disease has in many cases changed the natural history of the malformation,
decompensation, or arrhythmia. The survival rate of newborns with ductus-dependent
heart defect is often improved by prenatal recognition of the disease (Bonnet et al. 1999;
Verheijen et al. 2001). 
Of 90 neonates operated on because of structural heart anomaly in the year 1999, only 15
had fetal diagnoses (17%). In many series, the detection rate has been higher, ranging
from 30 to 50% (Kitchiner 2004). The actual detection rate is even lower, because not all
infants born with cardiac anomalies need an early operation or hospitalization. 
During the study period, a system of planned delivery was organized at the Hospital for
Children and Adolescents in Helsinki. Nevertheless, overall neonatal mortality from
cardiac malformation and from functional heart disease was high, 49% and 33%,
respectively. HLHS was associated with the highest mortality (87%), mainly because
prior to 1995 no active interventions were attempted. Between 1995 and 1999, eight
fetuses diagnosed with HLHS were born alive, but only three of these underwent surgery.
Although numbers of patients are very small, this finding is similar to others: only 25 to
30% of cases with fetal diagnoses of HLHS undergo surgery (Bard et al. 1998; Brackley
et al. 2000; Andrews et al. 2001). Of one group of 10 ductus-dependent anomalies (not
HLHS), all treated with prostaglandin, 7 deaths were attributable to severe cardiac
incompensation detected in utero. Although this group of infants should have received
major benefit from prenatal diagnosis (Bonnet et al. 1999), in this study benefits could
not be shown, mainly because of the limited number of cases of single anomalies. 
Ethics 
Parental counseling is a difficult and important aspect of fetal detection of cardiac
disease. The aims of counseling are to provide an accurate diagnosis of the malformation,
to outline the options available, to explain prognoses, and to help parents achieve the
form of management best for them (Allan and Hornberger 2000).  It is important to have
knowledge of the precise cardiac diagnosis, the associated extracardiac malformations or
chromosomal anomalies, the natural history of the malformation in fetal life, and the
surgical options (Fesslova et al. 1999; Lutin et al. 1999). Unsatisfactory professional
knowledge of long-term results from these difficult lesions is one of the weakest areas in
our counseling (Eapen et al. 1998). 
In Studies I to II, we could not show that the patients received any actual benefits from
fetal diagnosis with regards to outcome. Our series corresponds to other reports, all of
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which have indicated a higher prevalence of more complicated heart defects and a higher
frequency of extracardiac and chromosomal anomalies detected prenatally than in infants.
In Study I, of the 93 fetuses with structural anomaly, 34 had univentricular heart. HLHS
had a very poor outcome in our series; only 3 of 15 patients had the Norwood operation.
The short-time outcome of this group of patients has improved both because of
improvement in surgical skills and in pre- and postoperative management. Infants with
univentricular lesions (not HLHS) had a survival rate of 50%. As in earlier reports, the
outcome was good with DORV and TOF; the mortality with VSD and AVSD was mainly
associated with extracardiac and chromosomal anomalies (Perolo et al. 2001). 
In retrospect, in Study III, it is obvious that the fetuses with atrial tachycardia did benefit
from the diagnoses and treatment. The problem with Studies I to II was that the patient
material was heterogenous, with a wide range of etiologies. 
Certainty of diagnosis
The certainty of any fetal cardiac diagnosis depends on the completeness of the fetal
echocardiogram. If the image quality is poor, the details of a malformation may be
difficult to define. The diagnosis of arrhythmia is usually quite easy. If a decision
concerning the continuation of a pregnancy rests on an incomplete or unsatisfactory
study, it should be repeated within a short time interval (Allan and Hornberger 2000).
According to the literature, false-positive diagnoses of structural heart disease are limited
to two types: ventricular septal defects and aortic coarctation (Perolo et al. 2001). Study I
included six false-positive diagnoses: five small muscular ventricular septal defects and
one coarctation of the aorta. 
In Study I, all the diagnoses of major heart defects were adequate; for complex structural
anomalies, additional minor defects (multiple muscular VSD, minor valve insufficiency,
coarctation of the aorta) appeared postnatally. Despite their fetal diagnoses, the neonates
with structural cardiac anomaly needed detailed echocardiography postnatally. The fetal
diagnoses were adequate for planning the follow-up in pregnancy, delivery, and imminent
neonatal management, but not for preparation for surgery (Leung et al. 1999).
In Study II, we found no additional cardiac malformations postnatally. In Study III, type
of arrhythmia did not change after birth, except in the case of two infants with AES who
developed SVT. 
Fetal follow-up
The course of an individual cardiac disease in fetal life depends on type of malformation.
Much fetal mortality and morbidity is explained by extracardiac malformations and
chromosomal anomalies (Allan et al. 1991; Fesslova et al. 1999). In our study, some
cases of cardiac failure occurred from simple cardiac defects without any actual
hemodynamic cause (VSD, ASD sec, CoA). In these cases, the cause may have been a
chromosomal anomaly (18-trisomy, Down`s syndrome), or have been multiple
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extracardiac malformations or placental insufficiency or both. As in the literature, we
found a risk of 8% for fetal death from structural heart disease (Fesslova et al. 1999;
Kitchiner 2004). In our study, risk for intrauterine death seems to be associated more with
the chromosomal anomalies than with the type of structural anomaly; fetal mortality was
only 3% in the fetuses with a normal karyotype. 
It is well recognized that cardiac malformations can change or progress with advancing
gestational age. In the presence of any obstructive lesions, growth of heart structures can
decrease, resulting in hypoplasia of the affected part (Hornberger et al. 1995; Simpson
and Sharland 1997). In cases of early diagnosis of a left or right heart obstructive lesion,
the possibility of development must be included and the fetus followed throughout the
pregnancy.
For cases of fetal arrhythmias or cardiac failure with intrauterine intervention, follow-up
is intense. The aim is to improve effective cardiac output, to prolong the pregnancy, and
to prevent prematurity and prenatal asphyxia. The decision to treat the fetus depends on
gestational age, signs of cardiac failure, and duration of tachycardiac episodes (Allan and
Hornberger 2000). Nowadays, preterm delivery of a hydropic fetus is avoided if possible,
because the outcome of such a premature infant is depressing. In Study II, of 10 hydropic
fetuses delivered prematurely (8 Cesarean section), only two are alive and in Study III, of
four hydropic fetuses delivered prematurely (all by Cesarean section), three died. In
Study III, hydropic fetuses had a much higher mortality (38% vs. 3.7%) as well as a
significantly lower mean gestational age at birth (33.6 weeks vs. 38 weeks) than the
nonhydropic fetuses. All the hydropic fetuses delivered prematurely originate from the
late 1980`s. Furthermore, two of them were treated with intravenous verapamil, which
caused bradycardia and worsened heart insufficiency. This finding is similar to that of
Frohn-Muller et al. (1995) and demonstrates why verapamil is not recommended during
early infancy. In our institution, verapamil has not been used in neonates since the
1990`s. 
Implications of fetal diagnosis in outcome
Structural heart disease (I):
The increasing prenatal detection of cardiac defects has led to a reduction in the birth
prevalence of difficult lesions (Brick and Allan 2002). In many countries, if a complex
heart defect is detected in a pregnancy of less than 20 weeks of gestation, over half the
parents will choose to interrupt the pregnancy (Allan and Hornberger 2000). In our study,
35% of our fetuses with a cardiac defect diagnosed before 24 weeks of gestation were
aborted. However, only 30% of mothers were referred to a pediatric cardiologist before
24 weeks of gestation, meening that only they had any option of interrupting the
pregnancy. Of the aborted fetuses, 70% had a complex cardiac anomaly with
univentricular heart or hypoplastic left heart syndrome; the remaining had a chromosomal
abnormality. No fetuses with the option of biventricular repair were terminated. In the
study by Fesslova et al. (1999), fetuses with biventricular anatomy were also aborted, and
in many countries, 50 to 60% of fetuses with univentricular heart are terminated if fetal
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diagnosis is done before week 24 of gestation (Brackley et al. 2000; Andrews et al.
2001). 
As shown in previous studies, for example Fesslova et al. 1999 an in-utero-diagnosed
heart defect is often associated with chromosomal or extracardiac anomalies. In our
study, the extent was 52% and 40%. These numbers are high compared with those of
others (Allan et al. 1991; Pradat 1997; Kitchiner 2004). Our higher occurrence of
chromosomal and extracardiac anomalies can be explained by the fact that our study
population was selected. (Indication for referral to a pediatric cardiologist was not only
arrhythmia but also abnormal four-chamber view, family history of congenital heart
disease, extracardiac malformation, or maternal diabetes.) The diagnoses of AVSD and
VSD (large inflow septum) were particularly predictive of chromosomal and extracardiac
abnormality, expecially if associated with growth retardation. As in the literature, 18-
trisomy, 21-trisomy, 13-trisomy, and Turner`s syndrome were the most frequent
(Thompson and Thompson 1986). Outcome was poor for both abnormal karyotype and
extracardiac anomalies: 73% and 48% of these fetuses died. HLHS, TOF, DORV,
tumors, PA+IVS, and RV hypoplasia were rarely found with chromosomal abnormalities.
These findings suggest that chromosomal evaluation of all fetuses with any cardiac
anomaly, regardless of gestational age, are wise in order to optimize intrauterine and
postnatal treatment. 
In accordance with previous studies (Fesslova et al. 1999; Hiippala et al. 2001),
intrauterine heart failure was identified as an unfavorable prognostic sign. Despite
intrauterine treatment, 64% of these fetuses died. Cardiac failure and arrhythmia were
most frequent in fetuses with univentricular heart (atrial isomerism) and tumors. Another
negative prognostic factor for outcome was associated anomalies (Fesslova et al. 1999;
Kitchiner 2004). Of the fetuses with an abnormal karyotype, 73% died.
Altogether, neonatal surgical mortality in Study I was higher than overall mortality after
neonatal heart surgery (25% versus <10%). This is in accordance with data showing a
low survival rate in fetal study populations (Fesslova et al. 1999; Allan and Sharland
2000; Kitchiner 2004). It seems that the more severe end of the spectrum of congenital
heart disease is diagnosed antenatally, and that these infants have a much higher
incidence of chromosomal and extracardiac abnormalities.
Functional heart disease (II):
In this study, overall mortality of fetuses with functional heart disease without cardiac
defects or arrhythmias was high, at 33%. In early manifestations of cardiac insufficiency -
such as pericardial effusion and tricuspidal regurgitation - mortality was equal to or less
than 25%, but when a fetus developed hydrops, mortality rose to 64%, as in Respondek et
al. (1996). If the pathogenesis of the cardiovascular disease was high-output cardiac
failure (anemia, volume overload, or arteriovenous fistula/teratoma), the risk for
developing hydrops was high.  These findings confirm results of other studies (Zosmer et
al. 1994; Sonntag et al. 1996). 
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Digoxin was administered to 9 fetuses with high-output cardiac failure. Although, in
retrospect, this intrauterine treatment did not improve prognosis, digoxin is known to
reduce the catecholamine response to congestive heart failure and to reduce filling
pressures. It is used for fetal cardiac failure due to arrhythmias and high-output states.
Laser treatments of the twin-twin communication can also lessen cardiac failure (Huhta
2004). 
 
One weakness of this study was the heterogeneousity of the study group. The etiology of
fetal cardiac decompensation is very complex, and a diverse group of pathologies may
result in the same kind of functional heart disease. Fetal outcome seems not to associate
only with the cardiac problem but also with the underlying pathology. 
Cardiac arrhythmias (III):
Atrial extrasystoles. Irregularity of fetal heart rhythm is usually caused by atrial
extrasystoles (Kleinman et al. 1985), and in the majority of cases, extrasystoles resolve
spontaneously either prenatally or early in the postnatal period. Several blocked atrial
extrasystoles can cause a ventricular rate of less than 100 beats per minute, which may
simulate fetal asphyxia. These have also been associated with subsequent development of
sustained supraventricular tachycardia either prenatally or postnatally (Simpson et al.
1997). In our study, frequency of blocked atrial extrasystoles was 7%, but none of the
fetuses developed atrial tachycardia in utero or after birth. 
Recent reports suggest that cardiac defects occur in only 0.3 to 2% of the fetuses with
atrial extrasystoles (Copel et al. 2000). Our study showed an incidence of cardiac
anomalies and tumors that was much higher: 9%, probably because of the selection of the
study population. The frequency of significant postnatal arrhythmias was 1%, similar to
that in earlier reports (Meijboom et al. 1994; Simpson and Marx 1994). 
Atrial tachycardia.  Control of atrial tachycardia was poorer in hydropic than in
nonhydropic fetuses, which confirms other findings and shows that fetal hydrops may
hinder transplacental transfer of antiarrhythmic agents (van Engelen et al. 1994; Simpson
and Sharland 1998; Kleinman and Nehgme 2004). Digoxin alone was effective in 54% of
our nonhydropic fetuses but in none of our hydropic fetuses. In the nonhydropic fetuses
with a second drug administered, sinus rhythm was achieved in 85% compared with 63%
in hydropic fetuses, findings also similar to those of studies showing that although
nonhydropic fetuses require only one drug in most cases, in the presence of hydrops, the
median number of drugs required is two (Sonesson et al. 1998). Direct fetal therapy has
been advocated to avoid the problems of transplacental transfer of antiarrhythmic drugs
(Hansmann et al. 1991; Flack et al. 1993). Direct fetal treatment by use of amiodarone
(triple route) was administered to six fetuses, three without hydrops and three with
hydrops; all converted to sinus rhythm. In two cases, bradycardia occurred, one of these
resulting in intrauterine death. Because of these complications, this form of therapy is no
longer in use in our institution. In this study, the electrical mechanism underlying the
arrhythmia was not studied, so could not help to guide our antiarrhythmic therapy
(Kleinman and Nehgme 2004).
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In fetal tachycardia, neonatal survival rates and incidence of complications are associated
with prematurity and presence of structural heart disease (Hansmann et al. 1991; Flack et
al. 1993; Simpson and Marx 1994; Simpson and Sharland 1998). Some studies show a
higher association of AT with hydrops than with SVT (Kleinman and Nehgme 2004), but
we were unable to confirm this in our subjects. In accordance with previous studies
(Naheed et al. 1996), our study confirms that prenatal delivery of a tachycardic baby is
problematic because of a high incidence of complications, and it should be avoided.
Prenatal therapy changed during the period of our study. Digoxin is also nowadays the
first drug used, but if not effective is combined with flecaine or sotalol. Neither
propranolol nor verpamil is used in our institution in intrauterine treatment.
The natural history of atrial tachycardia is a spontaneous resolution during the first year
of life (Benson et al. 1987). In our study, 65% of the nonhydropic and 80% of the
hydropic fetuses received antiarrhythmic therapy postnatally, and at follow-up, a
significantly higher neurological morbidity was evident in infants born hydropic (40%)
than in others (12%), but this was partly due to prematurity. On the basis of both our and
previous observations (Sonesson et al. 1996), we conclude that a fetus with atrial
tachycardia, especially with hydrops, is at increased risk for cerebral complications. 
Atrioventricular block. Our Study III showed that antenatal findings associated with poor
prognoses were in-utero cardiomyopathy and autoimmune myocarditis with pericardial
effusion or hydrops or both.  In eight of ten fetuses with cardiac failure, heart rate was 55
beats per minute or lower. These findings confirm previous ones: low heart rate is
associated with severe cardiac failure and a greater likelihood of poor outcome (Groves et
al. 1995). The literature includes no reports dealing with in-utero autoimmune
myocarditis, only late-onset myocarditis with fatal outcome (Eronen et al. 2000).  
The prognosis of atrioventricular block accompanied by structural heart disease is poor,
particularly with atrial isomerism (Schmidt et al. 1991). Our neonatal survival rate was
50%, but with left atrial isomerism only 25%. Onset of fetel hydrops in this group of
patients is an ominous sign, and termination of pregnancy may be considered (Rosenthal
2000). None of our patients had hydrops, but their prognosis still was poor.
Persistent fetal bradycardia and ventricular extrasystoles
Because of the high risk for cardiac anomalies, fetuses with sinus bradycardia and
ventricular extrasystoles require careful evaluation of their cardiac anatomy (Schmidt et
al. 1991; van Engelen et al. 1994). In Study III, risk for cardiac anomalies was high.
Because both fetal bradycardia and ventricular extrasystoles are very rare, the reports are
mostly observations with small numbers of patients. Our number of these arrhythmias
was very small, and the study population was selected; the indication for referral was not
always an arrhythmia, but sometimes was fetal hydrops, an extracardiac anomaly, or a
small-for-date fetus.
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8.2. Neonatal Studies (IV)
Earlier echocardiographic studies have shown in growth-retarded fetuses a redistribution
of circulation, diverting highly oxygenated blood from other tissues to sustain the growth
of the brain, as well as a shift of cardiac flow in favor of the left side of the heart (Rizzo
and Arduini 1991; Rizzo et al. 1996), but the immediate postnatal cardiovascular
consequences of growth restriction have not been elucidated. We show that in low birth-
weight infants, fetal growth restriction is associated with alterations in early
hemodynamic adaptation.
In growth-retarded human fetuses, an increased LVO and decreased ratio of right to left
ventricular output occurs (Rizzo and Arduini 1991). The septal and left ventricular
hypertrophy we observed in SGA infants could be explained by an increased left
ventricular work-load in utero, resulting from a shift in the left-to-right output ratio or
from impaired systemic vascular resistance. Because we found no significant differences
in LVEF and LVFS between the AGA and SGA infants, the altered LVO after
intrauterine growth retardation is more likely explained by changes in vascular resistance
than by contractility.
SGA infants may have a limited capacity for postnatal cardiac adaptation, since they are
unable to increase their LVO postnatally, in contrast to AGA infants. Since there was no
initial difference in intravascular volume between these groups, it is not likely that the
LVO increase was due to an expanded preload. No differences appeared in vasopressor
therapy, in respiratory distress, blood pressures, or ductal patency between the study
groups to explain the differences in LVO. 
The cardiac hypertrophy observed in our SGA infants is in accordance with hypertrophy
of both ventricles in growth-retarded fetuses (Veille et al. 1999). The most apparent
mechanism is prolonged exposure to an increased myocardial workload, which could also
account for the elevated BNP in the SGA infants. Circulating BNP levels are known to
correlate with ventricular dysfunction, left ventricular wall thickness, and left ventricular
mass (Lerman et al. 1993).
Taken together, the present observations: altered postnatal pattern of LVO, cardiac
hypertrophy, and increased BNP, suggest that SGA infants are exposed to significant
cardiovascular stress in utero. Accumulating evidence has linked fetal growth retardation
to adult cardiovascular disease (Barker 1998). It still remains to be established whether
the hemodynamic changes observed in SGA newborns can lead to permanent
cardiovascular alterations. Among our newborns, no differences emerged in blood
pressures. Ley et al. have made the same observation in older children: changes in fetal
hemodynamics associated with intrauterine growth retardation do not appear to contribute
to a later increase in blood pressure (Ley et al. 1997). 
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CONCLUSIONS 
For diagnosing cardiovascular disease in the fetal and perinatal period, echocardiography
is reliable. Etiology in fetal cardiovascular pathology is heterogenous. One poor
prognostic indicator is fetal hydrops.
1) Congenital structural heart disease represents an important health problem,
because of its consequences for perinatal morbidity and mortality. 
Negative prognostic indicators for outcome are heart failure and extracardiac and
chromosomal anomalies.
2) Functional heart disease in utero is associated with a broad variety of inherited
and intrauterine conditions. Negative prognostic indicators are heart failure and
preterm delivery. If the etiology is high-output cardiac failure, the risk for fetal
hydrops is high.
3) All fetal arrhythmias except atrial extrasystoles are associated with a moderately
high risk for fetal distress. In cases of compromise, fetal and neonatal prognosis is
poor and is an indication for perinatal medication. After the neonatal period, the
prognosis is good. 
Both in fetal tachycardia and in atrioventricular block, preterm delivery results in
a high incidence of complications. 
The risk for neurological impairment must be taken into consideration, especially
inregard to hydropic fetuses.
4) In newborn low birth-weight infants, intrauterine growth retardation is associated
with alterations in cardiac adaptation as well as with septal and left ventricular
hypertrophy.
SGA fetuses and infants may be exposed to an increased risk for circulatory
failure.
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